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A B S T R A C T
Background
The decline in circulating oestrogen around the time of the menopause often induces unacceptable symptoms that affect the health and
well being of women. Hormone replacement therapy (both unopposed oestrogen and oestrogen and progestogen combinations) is an
effective treatment for these symptoms. In women with an intact uterus, unopposed oestrogen may induce endometrial stimulation and
increase the risk of endometrial hyperplasia and carcinoma. The addition of progestogen reduces this risk but may cause unacceptable
symptoms, bleeding and spotting which can affect adherence to therapy.
Objectives
The objective of this review is to assess which hormone replacement therapy regimens provide effective protection against the develop-
ment of endometrial hyperplasia and/or carcinoma with a low rate of abnormal vaginal bleeding.
Search strategy
Electronic searches for relevant randomised controlled trials of the Cochrane Menstrual Disorders and Subfertility Group Register of
Trials, MEDLINE, EMBASE, PsycLIT, Current Contents, Biological Abstracts, Social Sciences Index and CINAHL were performed.
Attempts were also made to identify trials from citation lists of review articles and drug companies were contacted for unpublished
data. In most cases, the corresponding author of each included trial was contacted for additional information.
Selection criteria
The inclusion criteria were randomised comparisons of unopposed oestrogen therapy, combined continuous oestrogen-progestogen
therapy and sequential oestrogen-progestogen therapy with each other and placebo administered over a minimum treatment period of
six months. Trials had to assess which regimen was the most protective against the development of endometrial hyperplasia/carcinoma
and/or caused the lowest rate of irregular bleeding.
Data collection and analysis
Twenty three RCTs were identified and five were excluded. The reviewers assessed the eighteen included studies for quality, extracted the
data independently and odds ratios for dichotomous outcomes were estimated. Outcomes analysed included frequency of endometrial
hyperplasia or carcinoma, frequency of irregular bleeding and unscheduled biopsies or dilation and curettage, and adherence to therapy.
Main results
Unopposed moderate or high dose oestrogen therapy was associated with a significant increase in rates of endometrial hyperplasia with
increasing rates at longer duration of treatment and follow up. Odds ratios ranged from 5.4 (1.4-20.9) for 6 months of treatment
to 16.0 (9.3-27.5) for 36 months of treatment with moderate dose oestrogen (in the PEPI trial, 62% of those who took moderate
dose oestrogen had some form of hyperplasia at 36 months compared to 2% of those who took placebo). Irregular bleeding and non
adherence to treatment were also significantly more likely under these unopposed oestrogen regimens with greater effects with higher
dose therapy. There was no evidence of increased hyperplasia rates, however, with low dose oestrogen.
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The addition of progestogens, either in continuous combined or sequential regimens, helped to prevent the development of endometrial
hyperplasia and improved adherence to therapy (odds ratios of 3.7 for sequential therapy and 6.0 for continuous therapy). Irregular
bleeding, however, was more likely under a continuous than a sequential oestrogen-progestogen regimen (OR = 2.3, 95% CI 2.1-
2.5) but at longer duration of treatment, continuous therapy was more protective than sequential therapy in preventing endometrial
hyperplasia (OR = 0.3, 95% CI 0.1-0.97). There was evidence of a higher incidence of hyperplasia under long cycle sequential therapy
(progestogen given every three months) compared to monthly sequential therapy (progestogen given every month). No increase in
endometrial cancer was seen in any of the treatment groups during the limited duration (maximum of three years) of these trials.
Reviewers’ conclusions
There is strong and consistent evidence in this review that unopposed oestrogen therapy, at moderate and high doses, is associated
with increased rates of endometrial hyperplasia, irregular bleeding and consequent non adherence to therapy. The addition of oral
progestogens administered either cyclically or continuously is associated with reduced rates of hyperplasia and improved adherence to
therapy. Irregular bleeding is less likely under sequential than continuous therapy but there is a suggestion that continuous therapy
over long duration is more protective than sequential therapy in the prevention of endometrial hyperplasia. Hyperplasia is more likely
when progestogen is given every three months in a sequential regimen compared to a monthly progestogen sequential regimen.
B A C K G R O U N D
Menopause means the cessation of menstruation and typically oc-
curs between 45-55 years of age with a mean age of about 51 years.
Women are said to be postmenopausal when menstruation has
ceased for 12 months. The decline in circulating oestrogen around
the time of the menopause can induce symptoms that affect the
well being and health of women; hot flushes, insomnia, declining
bone mass, night sweats, mood disturbances and urogenital atro-
phy have all been reported. As the population continues to grow
older, there has been an increased focus on the effects of ageing.
Oestrogen replacement therapy has been utilised for the treatment
of many of themenopausal symptoms, particularly hot flushes and
dry vagina.
Several studies have suggested a causal relationship between unop-
posed oestrogen replacement therapy (daily use of oestrogen with-
out the addition of progestogen) and the induction of endometrial
hyperplasia and carcinoma (Ziel 1975; Smith 1977; Gardan 1977;
Antunes 1979; Grady 1995). Endometrial hyperplasia is regarded
as a precursor of endometrial cancer but progression is dependent
on type of hyperplasia (Kurman1985;Terakawa1997). The risk of
hyperplasia and/or carcinoma appears to increasewith higher doses
and increased duration of unopposed oestrogen treatment. Adding
a progestogen to oestrogen replacement therapy significantly re-
duces the risk of hyperplasia (Whitehead 1977; Cust 1990; Ud-
off 1995), but can result in premenstrual symptoms and vaginal
bleeding and spotting, which is undesirable to many women. This
is often given as a reason not to continue hormone replacement
therapy (Ellerington 1992).
The endometrial histology shows an inactive phase in 100% of the
women given continuous daily progestogen but in only 25% of
those on cyclic (sequential) progestogen (both in conjunction with
continuous oestrogen). Withdrawal bleeding occurs with cyclic
(sequential) regimens (daily use of oestrogen with cyclical use of
progestogen) in themajority of women, whereas irregular bleeding
and spotting occurs with continuous (daily use of oestrogen and
progestogen) or oestrogen alone regimens in approximately 50%of
women, but these bleeding episodes diminishwith time in those on
continuous progestogen and oestrogen. For women who are con-
sidering long term hormone replacement therapy for the preven-
tion of osteoporosis or reduction of risk of cardiovascular events,
most prefer a continuous regimen of oestrogen-progestogen for
the maintenance of an atrophic endometrium with no bleeding.
The aim of this review is to assess which of the hormone replace-
ment regimens, unopposed oestrogen or oestrogen-progestogen
administered either continuously or cyclically, provides the best
protection against the development of endometrial hyperplasia or
carcinoma and the lowest rate of irregular bleeding and non ad-
herence to therapy.
O B J E C T I V E S
To assess which of the hormone replacement therapy regimens
provides the most effective protection against the development of
endometrial hyperplasia and/or carcinoma and the lowest rate of
abnormal vaginal bleeding.
We wished to assess the following:
1. Effect of unopposed oestrogen therapy on the frequency of
endometrial hyperplasia/carcinoma and irregular vaginal bleeding
when compared to placebo.
2. Effect of unopposed oestrogen therapy on the frequency of
endometrial hyperplasia/carcinoma and irregular vaginal bleeding
when compared to oestrogen and progestogen therapy.
3. Effect of oestrogen and progestogen therapy on the frequency of
endometrial hyperplasia/carcinoma and irregular vaginal bleeding
when compared to placebo.
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4. Effect of continuous oestrogen plus progestogen therapy on
the frequency of endometrial hyperplasia/carcinoma and irregular
vaginal bleeding when compared with sequential oestrogen plus
progestogen therapy.
5. Effect of sequential oestrogen plus progestogen therapy (pro-
gestogens given once a month) on the frequency of endometrial
hyperplasia/carcinoma and irregular vaginal bleeding when com-
pared with sequential oestrogen plus progestogen therapy (pro-
gestogens given once every 3 months).
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
All randomised controlled trials of oestrogen or combined
oestrogen/progestogen therapy versus placebo, oestrogen ver-
sus combined oestrogen/progestogen (sequential and continu-
ous therapy), oestrogen/progestogen (continuous) versus oestro-
gen/progestogen (sequential), and sequential O + P (progestogen
once a month) versus O + P (progestogen once every 3 months)
with a minimum treatment period of 6 months. This review has
not included ’dose finding’ trials where different doses of oestrogen
and/or progestogen are compared. These trials will be included in
a separate review.
Types of participants
Postmenopausal women with an intact uterus, defined as women
whohave notmenstruated formore than sixmonths andwhohave
a serum FSH greater than or equal to 40 IU/L. It is recognised
that this criterion is more liberal than the more usual definition
of postmenopausal status (last menses greater than or equal to 12
months prior) but the majority of trials use this more liberal cri-
terion and postmenopausal status is often further confirmed by
FSH levels. The definition includes women who have undergone a
natural menopause and women who have had bilateral oophorec-
tomy (removal of both ovaries).
The participants can be recruited from any health care setting or
from advertisements.
Exclusion criteria:
Perimenopausal women (menstruation less than 6 months prior
to study)
Intercurrent major disease
Previous HRT (hormone replacement therapy) within one month
of commencement of the study
Any contraindication to HRT (either unopposed oestrogen or oe-
strogen + progestogen therapy)
Types of intervention
Interventions administered for a period of 6 months or greater.
1. Oestrogen versus placebo
2. Oestrogen versus combined oestrogen/progestogen, either se-
quential (cyclic) or continuous
3. Combined oestrogen/progestogen (sequential or continuous)
versus placebo
4. Combined oestrogen/progestogen (continuous) versus oestro-
gen/progestogen (sequential)
5. Sequential oestrogen/progestogen (progestogen once a month)
versus sequential oestrogen/progestogen (progestogen once every
3 months).
Types of outcome measures
1. Frequency of endometrial hyperplasia (of any type) or carcinoma
(assessed by endometrial biopsy or histology)
2. Irregular bleeding patterns, either number of women with irreg-
ular bleeding and/or spotting or number of cycles with irregular
bleeding/spotting
3. Requirements for other medical and surgical therapy (unsched-
uled endometrial biopsies or dilatation and curettage (D&C))
4. Adherence/compliance to therapy
S E A R C H S T R A T E G Y F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: search strategy
Electronic searches were performed of the Trials Register of
the Cochrane Menstrual Disorders and Subfertility Group,
MEDLINE, EMBASE, Current Contents, Biological Abstracts,
Social Sciences Index, PsycLIT and CINAHL for publications
which described randomised trials of oestrogen versus
oestrogen-progestogen or placebo or oestrogen-progestogen
versus placebo or combined continuous oestrogen-progestogen
versus sequential oestrogen-progestogen therapy and their
impact on endometrial hyperplasia and bleeding patterns in
menopausal women. The search strategy developed by the
Cochrane Menstrual Disorder and Subfertility Group was used
together with the additional terms:
exp climacteric/
exp menopause/
climacter$.tw.
menopaus$.tw.
“postmenopaus$”.tw.
“post-menopaus$”.tw.
“post menopaus$”.tw.
endometrial hyperplasia/
(endometri$ adj5 hyperplasia).tw.
exp estrogens/
contraceptives, oral, combined/
estrogen replacement therapy/
progestational hormones/
hormone replacement therapy.tw.
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HRT.tw.
progest$.tw.
bleeding pattern$.tw.
Citation lists of included trials, conference abstracts and
relevant review articles were also searched, relevant journals
handsearched for additional trials (see Review Group details for
more information) and drug companies contacted for details of
unpublished trials. It was planned to contact the corresponding
author of included trials where data were not in a form suitable
for extraction or where information relating to the study was not
made explicit.
M E T H O D S O F T H E R E V I E W
Selection of trials
The selection of trials for inclusion in the review was performed by
three of the reviewers (AL, AS and RJ) after employing the search
strategy described previously.
Quality assessment
Included trialswere assessed independently by four of the reviewers
(AL, and either RJ, AS, or HR) for the following quality criteria
and methodological details:
Trial characteristics
1. Method of randomisation
2. Presence or absence of blinding to treatment allocation
3. Quality of allocation concealment
4. Number of women randomised, excluded or lost to follow up
5. Whether an intention to treat analysis was done
6. Whether a power calculation was done
6. Duration, timing and location of the study
Characteristics of the study participants
1. Age and any other recorded characteristics of women in the
study
2. Other inclusion criteria
3. Exclusion criteria
Interventions used
1. Doses and types of unopposed oestrogen therapy used
2. Doses, types and regimens of oestrogen-progestogen therapy
used
Outcomes
1. Methods used to measure endometrial hyperplasia
2. Types of endometrial hyperplasia
Data management
Data extraction was performed independently by four of the
reviewers (AL, and either AS, CF or HR) using forms designed
according toCochrane guidelines. Any discrepancies were resolved
by discussion. Quality of allocation concealment was graded as
either A (adequate), B (unclear) or C (inadequate). Three of the
reviewers (CF, HR and AS) were experts on clinical issues and two
reviewers had statistical or methodological expertise (AL and RJ).
Where necessary, additional information on trial methodology or
actual original trial data was sought from the corresponding author
of any trials that appeared to meet the eligibility criteria.
Statistical analysis
Statistical analysiswas performed in accordancewith the guidelines
for statistical analysis developed by the Menstrual Disorders and
Subfertility Group. Heterogeneity between the results of different
studies was examined by inspecting the scatter in the data points
and the overlap in their confidence intervals and, more formally,
by checking the results of the chi-squared tests. A priori, it was
planned to look at the possible contribution of differences in
trial design to any heterogeneity identified in this manner. Where
possible, the outcomes were pooled statistically.
For dichotomous data (for example, proportion of patients with
hyperplasia or carcinoma), results for each studywere expressed as a
odds ratio with 95% confidence intervals and combined for meta-
analysis with RevMan software using the Peto-modified Mantel-
Haenszel method. All of the outcomes were categorised so that a
high value represented a harm or negative consequence rather than
a benefit of treatment. Thus, a negative consequence of treatment
is represented in the graphs as a mean and confidence interval on
the right of the centre line.
The main analyses were based on eighteen trials although not all
trials assessed all of the outcomes. However, we also planned a
priori sensitivity analyses based on:
i) Trials with adequate concealment (score A) versus trials with
uncertain or inadequate methodology (score B or C).
ii) Trials with double blinding versus trials with either single or no
blinding.
iii) Trials with intention to treat analysis versus those without ITT
analysis.
iv) Trials with < 20% withdrawals versus those with >20%
withdrawals.
v) Trials with details on type of hyperplasia diagnosed (trials where
all types of hyperplasia are included in the assessment versus
trials with simple hyperplasia excluded from the assessment of
hyperplasia).
Post-hoc sensitivity analysis was also performed based on:
i) Trials where the primary outcomes were the outcomes assessed
in this review versus trials where incidence of hyperplasia and
irregular bleeding were secondary or merely reported incidentally.
D E S C R I P T I O N O F S T U D I E S
Twenty three studies were identified but five of these were sub-
sequently excluded. Two of the excluded studies were located by
handsearching and published in abstract form and it was unclear
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whether women were randomised to treatment groups. The par-
ticipants for another excluded study were hospitalised for chronic
diseases, which is an exclusion criterion. For the remaining two
studies, some participants had diagnosed endometrial hyperplasia
at baseline (see Excluded Studies Table).
Data extraction was performed on the eighteen included trials,
which involved a total of 5247 participants, although not all of
these completed the total period of, follow up or were included in
an intention to treat analysis.
The trials took place in Chile (1), Denmark (5), Canada (1), Fin-
land (1), Japan (1), multi centre trial in Scandinavia (1), USA (7,
some of which were multi centre) and a large trial with 33% of
the total trial participants considered in the review was distributed
in 99 centres in the USA and Europe (MSG 1994). Most of the
included trials required that women be postmenopausal and this
was defined in all but 2 trials as cessation of bleeding for 6 months
or more prior to entry into the study. In these two trials, par-
ticipants were required to have an FSH>=40IU/L or within “the
postmenopausal range”. Participants ranged in age from 40 to 65
years although most patients were in the early menopause with
the requirement that women should be within five or less years
of their last spontaneous menstrual bleeding. Results can thus be
generalised only to women in the early postmenopause rather than
all postmenopausal women. Most of the trials also required that
women have an intact uterus or this was implied by the require-
ment for an endometrial biopsy at baseline, exclusion criterion of
previous gynaecological operation or the nature of the primary
outcomes. Full details of the inclusion and exclusion criteria are
found in the Table of Included Studies. Common exclusion cri-
teria were malignancy, chronic illness, or use of contraindicated
medications.
A wide variety of oestrogen alone or oestrogen and progestogen
combinationswere used as interventions in the included trials. Un-
opposed oestrogens included conjugated equine oestrogen (CEE),
ethinyl oestradiol (EE), micronised 17B-estradiol (E2), estrone
sulphate (EIS) and esterified oestrogens (ESE). Most of the unop-
posed oestrogen studies compared different doses of the same drug
with placebo. These oestrogens cannot be considered equal. They
vary in their dose equivalency and have different metabolic effects
on different tissues or end organs. In order to make meaningful
comparisons, oestrogens were grouped into ’low’, ’moderate’ and
’high’ dose subgroups. The allocations of different types and doses
of oestrogens to these groupings were made according to the ad-
vice of experts (France 1998; MacLennan 1998; Ansbacher 1994;
O’Connell 1998). Disagreement persists among clinical experts,
however, regarding categorisation of oestradiol in the moderate
range and two different doses (1 and 2mg) of this oestrogen have
been included in this category.
In some trials, unopposed oestrogen treatment (O) was compared
with oestrogen/progestogen combined treatment (O + P), either
continuous or sequential (cyclic). Progestogens used in the com-
bined treatment included norethisterone acetate (NA), medrox-
yprogesterone acetate (MPA), micronised progesterone (MP),
cyproterone acetate (CPA), desogestrel (DG), and levonorgestrel
(LNG).
In the analysis, continuous and sequential O + P regimens were
evaluated separately. For each type of regimen, different doses were
compared and then combined in a total estimate of effect between
O and O + P.
The effects of sequential therapy were evaluated separately for dif-
ferent doses and duration of progestogen treatment and then com-
bined in a pooled estimate. In this review, duration of progestogen
therapy varied from 11 to 14 days and was given at different times
in the treatment cycle. There is evidence that progestogens must
be taken for at least ten days per month to reduce the risk of en-
dometrial hyperplasia and carcinoma (Whitehead 1981) but some
more recent studies suggest that progestogens could be given for
at least 12 days (Sturdee 1994; Whitehead 1987). It was planned
to assess separately the effects of cyclical progestogen given for less
than and more than ten days but none of the included studies
were in the former category. A future review is planned to compare
duration and dosage of cyclical progestogen therapy.
Where there was only one comparison group of unopposed oe-
strogen and two or more groups with different O + P doses (MSG
1994; PEPI 1995), it was necessary to combine the two O + P
groups so the comparative unopposed oestrogen group was not
double counted.
The effects of O + P treatment, continuous and sequential, versus
placebowere also evaluated separately. In these comparisons, where
there was only one comparison group of placebo, the groups with
different dosages of O + P were combined (CHART 1996).
Duration of treatment in the included trials ranged from six
months to three years but the majority of studies assessed treat-
ment over either one or two years.
The primary outcomes were frequency of endometrial hyperplasia
or carcinoma and frequency of unscheduled or irregular bleed-
ing but not all of the trials evaluated both of these. Endometrial
hyperplasia was invariably confirmed by endometrial biopsy and
reported at six, 12, 24 and 36 months but not by all studies. Most
studies included any type of hyperplasia as a hyperplasia outcome
but in three studies, the different types of hyperplasia were distin-
guished. Sensitivity analysis was performed with the results of the
trials where simple hyperplasia was excluded from the assessment
of hyperplasia compared with the results of trials where all types
of hyperplasia were included in the assessment. Incidence of en-
dometrial carcinoma was measured as an outcome in some studies
but no trials were not of sufficient size or duration to adequately
determine this outcome.
Unscheduled or irregular bleeding was either recorded daily on a
calendar by participants or elicited from questioning the patient
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about their bleeding patterns. In one trial (MSG 1994), ’spot-
ting’ was distinguished from ’bleeding’ and the number of cy-
cles of irregular bleeding and irregular spotting were evaluated
separately. All other studies assessing bleeding patterns reported
on the proportion of women in the treatment group with break-
through or irregular bleeding. This was evaluated separately in the
review as bleeding occurring within six months or occurring at
a longer duration of time. All included trials assessing these out-
comes distinguished carefully between ’unscheduled’ (irregular or
’unexpected’) bleeding and regular or withdrawal bleeding. Reg-
ular bleeding was invariably defined as bleeding occurring dur-
ing the treatment free week during sequential therapy or from
day 21 of the treatment cycle to day one of the following cycle.
Withdrawal bleeding, which usually accompanies sequential O +
P treatment, was not considered in this review since it is an ex-
pected outcome of this type of regimen.
A small number of trials (Ettinger 1992; Hagen 1982; Harris
1991; Notelovitz 1996; Heikkinen 1997; Mizunuma 1997) as-
sessed change in bone density, lipid profile and climacteric symp-
toms as the primary outcomes and effects on the endometrium
and frequency of unscheduled bleeding were secondary outcomes.
A proportion of participants in most of these trials had a hys-
terectomy and endometrial effects and bleeding were separately
assessed in subgroups. This was taken into account in a sensitivity
analysis.
The frequency of unscheduled biopsies or dilation and curettage
was measured in one large trial (PEPI 1995) and non adherence
to treatment because of adverse events related to treatment was
assessed in 10 trials.
One trial, written in Spanish, was translated by Ms Christine
Aguilar of the San Antonio Cochrane Centre.
M E T H O D O L O G I C A L Q U A L I T Y
All eighteen studies were randomised but in nine no details were
provided of themethod. One trial had randomisation by “random
sampling numbers” but no details were given of adequate conceal-
ment of allocation. These ten trials were classified with an allo-
cation score of B (unclear allocation concealment). The remain-
ing eight trials were classified as A, adequate concealment prior
to allocation. All of the trials were double blinded except for six;
in three of these (Marslew 1991; Marslew 1992; Williams 1990),
the assessor was blinded and not the participants and in the re-
maining three trials blinding was not clear. Twelve of the trials
had a placebo control group. In the remaining six trials, one trial
compared two different doses of unopposed oestrogen with the
same doses of O combined with cyclic progestogen for 11 days
(Gelfand 1989), one trial compared a standard dose of unopposed
oestrogen with two different continuous O + P regimens and two
different sequential O + P regimens (MSG 1994), one trial com-
pared a standard dose of unopposed oestrogen with two different
continuous O + P regimens and a no treatment group (Mizunuma
1997), one trial compared a short cycle sequential O + P regimen
with a long cycle O + P regimen (progestogen given once a month
compared toprogestogen givenonce every threemonths cyclically)
(Scandinavia 1996) and two trials compared multiple continuous
O + P regimens with a sequential O + P regimen (Williams 1990,
Luciano 1993).
Unblinding occurred in 38 women in the PEPI trial (31 of those
receiving the unopposed oestrogen regimen, four receiving one
of the oestrogen and progestogen regimens and three receiving
placebo) because of endometrial biopsy results classified as com-
plex hyperplasia, atypia or cancer.
The included trials ranged in size from 36 to 1724 participants
with the three largest including more than 500 women (CHART
1996, n=1265; MSG 1994, n=1724; PEPI 1995, n=596). Six of
the large trialsweremulti centre trials and in the remaining12 trials
women were recruited from a single centre. All trials had a parallel
group design. Two trials had performed a power calculation for
sample size and analysis was by intention to treat (ITT) (Harris
1991; PEPI 1995), two trials had power calculations and no ITT
analysis (CHART 1996; MSG 1994), one trial had performed
a power analysis (with no ITT) but the numbers of participants
were not adequate (Mizunuma 1997) and one trial had only ITT
analysis (Notelovitz 1996).
Losses to follow up and withdrawals were common, particularly
in the larger trials and trials with long duration. In the CHART
study, 570 women (45%) had withdrawn (out of a total of 1265)
by the conclusion of the trial at two years. In this trial, a priori
stopping rules were applied for participants who developed hyper-
plasia and consequently a proportion of subjects in Group eight
(10mcg daily of oral ethinyl estradiol (EE2) continuously) were
terminated from the study early owing to a high rate of hyperpla-
sia. All remaining treatment groups had similar rates of withdrawal
that ranged from 22% to 30% and excluding the high dose oestro-
gen group, over 73% of the subjects completed the study. In the
other study with a very high proportion of withdrawals (Gelfand
1989), 54 women (31%) withdrew during the study for medical
reasons but the withdrawals were not comparable between treat-
ment groups. A further 24 women (14%) were under treatment at
the conclusion of the study and went on to complete their medica-
tion but their data were not included in the final analyses because
their treatment was not complete. Of the remaining trials, three
had withdrawals greater than 20% (Harris 1991, 23%; Marslew
1991, 22%;Mizunuma 1997, 31%) but the former study had ITT
analysis for one of the outcomes, frequency of irregular bleeding.
The other 12 trials had withdrawals ranging from 4% to 20%
and in one trial (Scandinavia 1996), the proportion of women
completing the trial was unclear. In another trial (Ettinger 1992),
the number of women randomised to treatment groups was not
specified. In the PEPI trial, 12% of the original participants failed
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to undergo endometrial biopsy at the end of three years but were
included in an ITT analysis.
R E S U L T S
The incidence of endometrial hyperplasiawas assessed at six, 12, 24
and 36 months. Not all of the studies reported the incidence rates
at these time intervals. No differentiation was made in the analysis
between the type of hyperplasia (simple, atypical or complex),
although this was reported in some studies. Where a study had
only one comparison or control group and several different doses
of the experimental group, it was necessary to combine the groups
with different doses in the analysis to avoid counting the control
group more than once.
The odds ratio (OR) was used instead of the relative risk because
there was an increase in events in the treatment group as the length
of follow up increased.
1. OESTROGEN VERSUS PLACEBO
Low dose
Therewere no significant differences overall in rates of endometrial
hyperplasia at six, 12 or 24 months or rates of irregular bleeding.
However, there was an increasing, although non-significant, trend
in rates of hyperplasia by duration of treatment for unopposed
oestrogenusers for the largest studywith 490participantswhen the
dose of 10ug of ethinyl oestradiol was used compared to the lower
doses (1ug, 2.5ug and5ug) in the treatment group (CHART1996)
(data not shown but is displayed in the publication). Adherence
to therapy was also not significantly different between treatment
groups in one small study.
Moderate Dose
There were significant differences in rates of endometrial hyperpla-
sia at 6months (OR=5.4, 95%CI 1.4-20.9), 12months (OR=8.3,
95% CI 4.2-16.2), 24 months (OR=9.6, 95% CI 5.9-15.5) and
36 months (OR=16.0, 95% CI 9.3-27.5) under oestrogen treat-
ment with increasing rates at longer duration of treatment and
follow up. Unscheduled biopsies or dilatation and curettage were
also significantly more likely under unopposed oestrogen treat-
ment (OR=19.9, 95% CI 12.0-33.1). In addition, irregular bleed-
ing was more likely after 6 months of treatment (OR=1.9, 95%
CI 1.1-3.5) and a greater proportion of women did not adhere
to their treatment regimens (OR=3.6, 95% CI 2.3-5.5). There
was no significant difference in rates of endometrial carcinoma
between treatment groups.
High Dose
Highly significant rates of endometrial hyperplasia were reported
with unopposed oestrogen therapy when compared with placebo
at all durations of follow up: at 6 months (OR=9.1, 95% CI, 3.6-
22.9), 12 months (OR=10.7, 95% CI 4.6-25.1) and 24 months
(OR=13.1, 95% CI 5.9-29.0), showing an increasing association
with increasing duration of treatment. Rates of irregular bleeding
were also higher after 6 months of treatment (OR=6.0, 95% CI
2.8-12.9) and women were more likely not to adhere to their
treatment regimen under oestrogen therapy (OR=6.8, 95% CI
3.4-14.0). No cases of endometrial carcinoma were reported in
the one small study that evaluated this outcome.
(2) OESTROGEN VERSUS OESTROGEN + PROGESTO-
GEN (continuous)
Rates of endometrial hyperplasia were significantly higher un-
der unopposed oestrogen treatment when compared with O + P
treatment although these rates did not appear to increase with
longer duration of follow up: at 6months (OR=14.2, 95%CI 6.4-
31.7), at 12 months (OR=15.0, 95% CI 9.7-23.2), at 24 months
(OR=14.5, 95% CI 8.5-24.8) and at 36 months (OR=17.1, 95%
CI 9.9-29.4). However, the odds ratios reported were pooled esti-
mates and varied according to the dosage of O and O + P, causing
significant heterogeneity at 24 months follow up. Unscheduled
biopsies or D& C were also more likely under unopposed oestro-
gen treatment (OR=20.8, 95% CI 12.5-34.5). Cycles of irregular
bleeding or spotting were significantly less likely during the 12
months of treatment with unopposed oestrogen (OR=0.8, 95%
CI 0.73-0.9 and OR=0.6, 95% CI 0.56-0.7) but it is unclear ex-
actly when during the year of treatment that these occurred. How-
ever, women were significantly more likely to adhere to their O
+ P treatment than the unopposed oestrogen treatment (OR=6.0,
95% CI 3.6-10.2). No rates of endometrial carcinoma were re-
ported.
(3) OESTROGEN VS OESTROGEN + PROGESTOGEN (se-
quential)
Endometrial hyperplasia was significantly more likely under un-
opposed oestrogen treatment when compared with sequential O
+ P treatment and this appeared to increase with longer dura-
tion of treatment and follow up; at 6 months (OR=11.6, 95% CI
5.5-24.5), 12 months (OR=15.2, 95% CI 10.0-22.9), 24 months
(OR=19.8, 95% CI 11.1-35.6) and 36 months (OR=22.6, 95%
CI 13.5-37.7). Unscheduled biopsies or D & C were also more
likely (OR=20.5, 95% CI 13.0-32.3) and irregular bleeding was
more common under treatment with oestrogen alone (OR=5.9,
95% CI 2.5-13.7 and OR=2.0, 95% CI 1.8-2.3). There was a sig-
nificant difference between treatment groups in rates of adherence
to therapy (OR=3.4, 95% CI 2.2-5.1) but there was significant
heterogeneity in the pooled estimate with women taking higher
dose oestrogen more likely to adhere to treatment and women
taking lower dose oestrogen showing a trend towards less adher-
ence in one study. There were no differences between treatment
groups in the number of cycles of irregular bleeding and no cases
of endometrial carcinoma.
(4) OESTROGEN + PROGESTOGEN (continuous) VS
PLACEBO
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No significant differences were found in the rates of endometrial
hyperplasia or carcinoma, unscheduled biopsies or D & C and
adherence to therapy between treatment groups. Irregular bleed-
ing, both within six months of starting treatment and at longer
durations of treatment, was however more likely under combined
oestrogen-progestogen therapy ((OR=6.4, 95% CI 2.7-15.1) and
(OR=6.1, 95% CI 2.7-13.7) respectively).
(5) OESTROGEN + PROGESTOGEN (sequential) VS
PLACEBO
Hyperplasia rates did not significantly differ between treatment
groups at 12 and 36 months after starting therapy but hyperplasia
was more likely under sequential therapy after 24 months (OR=4,
95% CI 1.2-14.0). When sensitivity analysis was performed ex-
cluding the small trial where hyperplasia was an incidental out-
come, this difference was no longer significant. Nevertheless, there
is a strong although non significant trend in favour of lower rates
in the placebo group at all durations of treatment and in most
cases results are from only one trial. There were no differences in
rates of endometrial cancer or irregular bleeding rates. However,
women in the placebo group were more likely to adhere to their
treatment than women in the combined sequential O + P group
(OR=3.5, 95% CI 1.5-8.1).
(6) OESTROGEN + PROGESTOGEN (continuous) VS OE-
STROGEN + PROGESTOGEN (sequential)
The rates of endometrial hyperplasia were not significantly differ-
ent between the two types of combined treatment at six, 12 and 24
months although there was an increasing trend over time in favour
of the continuous therapy group. At 36 months, the frequency
of hyperplasia was significantly lower under sequential treatment
(OR=0.3, 95% CI 0.09-0.97). There were no significant differ-
ences between groups in the rates of carcinoma and adherence to
therapy. There were also no significant differences between groups
in the proportion of women with irregular bleeding both within
6six and after six months of treatment although results were het-
erogeneous and the pooled OR was misleading. In the large MSG
trial, there were higher rates of cycles with irregular bleeding and
spotting in the continuous O + P treatment group ((OR=2.3, 95%
CI 2.1-2.5) and (OR=1.6, 95% CI 1.5-1.8) respectively).
(7) OESTROGEN + PROGESTOGEN (sequential, 1 month cy-
cle)VSOESTROGEN+PROGESTOGEN(sequential, 3month
cycle)
Rates of endometrial hyperplasiawere significantly increased in the
long cycle treatment group after 12 and 36 months of treatment
in one multi centre study in Scandinavia which was discontinued
as a result (OR=0.11, 95% CI 0.03-0.52 and OR=0.18, 95% CI
0.06-0.49 respectively). This finding was not found in one other
multi centre after 24 months of treatment. Adherence to therapy
and rates of endometrial cancer did not differ between treatment
groups.
SENSITIVITY ANALYSES
For many of the comparisons, the outcomes were recorded by only
one or two trials and sensitivity analysis could not be performed.
Where more trials were included, the exclusion of poorer quality
trials usually did not alter the results markedly. However, where
moderate dose oestrogen was compared with placebo, the OR for
endometrial hyperplasia at 24 months increased from 9.5 (5.9-
15.4) to 11.6 (6.9-19.4) with the exclusion of the poorer quality
trials and there were also increases in the odds ratios for endome-
trial hyperplasia at 6 and 12 months when unopposed oestrogen
was compared with oestrogen-progestogen therapy. However, ir-
regular bleeding after 6 months of treatment was not significantly
different between women taking moderate dose oestrogen and
placebo after the exclusion of the poorer quality trials (Ettinger
1992; Harris 1991) (previously, OR=1.9 (1.05-3.46)). This result
is likely to be caused by lower power; there was little heterogeneity
in the initial results and the odds ratio was almost identical with
and without the excluded trials. Sensitivity analysis also compared
the results found according to any type of hyperplasia with the re-
sults where diagnosis of hyperplasia excluded the simple form but
the direction of the results was not altered. No other differences
were found in the sensitivity analyses.
HETEROGENEITY
There was significant heterogeneity in the pooled results for non
adherence to therapy when unopposed oestrogen was compared
with oestrogen-progestogen sequential therapy but different doses
of oestrogen were pooled for the estimate. If the doses of oestrogen
are examined separately, women were significantly more likely to
not adhere to their treatment when taking unopposed oestrogen
(CEE 0.625mg) when compared to women taking the combined
O + P regimens (CEE 0.625mg + MPA 5mg or MPA 10mg or
MP 200mg) but significantly more women did not adhere to their
treatment in the O + P group compared to the O group where the
dose of oestrogen was increased to CEE 1.25mg in both compar-
ison groups. The reason for this discrepancy is not clear but sensi-
tivity analysis with the exclusion of the Gelfand trial (with a high
proportion of withdrawals) suggests that women are more likely
to adhere to the combined regimen compared with the unopposed
oestrogen regimen.
Significant heterogeneity was also found in the pooled estimate
for incidence of irregular bleeding both within 6 months and after
6 months of treatment when continuous O + P was compared
with sequential O + P therapy. All of the included trials for these
outcomes were regarded as poorer quality trials because of either
unspecified concealment, lack of double blinding or analyses not
by intention to treat and so the pooled estimates must be regarded
with caution. The largeMSG trial, however, reported significantly
more cycles with irregular bleeding and spotting in the group of
women who took continuous as opposed to sequential O + P
therapy and this result is likely to be a more valid indication of the
frequency of irregular bleeding.
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D I S C U S S I O N
Most of the RCTs included in this review have studied recently
postmenopausal women (within five years of the menopause) and
thus the findings are more applicable to this group than older
postmenopausal women.
The assessment of endometrial hyperplasia in this review is clin-
ically important because it is associated with an overall increased
risk of endometrial cancer, although this risk differs according to
the type of hyperplasia diagnosed. There is evidence that untreated
simple hyperplasia without atypia progresses infrequently over a
13 year period to carcinoma while this risk is greater in women
with complex hyperplasia (Kurman 1985). Untreated hyperplasia
with atypia is more likely to progress to cancer (Kurman 1985;
Terakawa 1997). Most of the trials included in this review have
distinguished ’hyperplastic’ endometrium of any type from other
types of endometrium but sensitivity analysis has also been per-
formed with the inclusion of only those trials that identified the
type of hyperplasia. When the simple type is excluded from the
definition of hyperplasia, the direction of the results has not dif-
fered but in some cases the strength of the increased risk has been
reduced.
The results confirm that the main adverse effect of unopposed
oestrogen replacement therapy was an increased risk of endome-
trial hyperplasia (of any type), although no excess risk was demon-
strated with low dose oestrogen. There were still too little data,
however, for declaring low-dose oestrogen as safe. There appeared
to be a dose-response relationship and a duration of treatment-
response relationship between unopposed oestrogen and risk of
hyperplasia, a result which has been well documented elsewhere
(Ziel 1975; Mack 1976; Grady 1995). This review, however, has
been able to group a number of different oestrogenic preparations
together with approximately similar therapeutic efficiency, which
gives added weight to the results of individual trials. Unscheduled
biopsies were also more likely under unopposed oestrogen therapy
since these are likely to be performed where there is concern about
endometrial stimulation and consequent hyperplasia.
The incidence of irregular bleeding after six months of treatment
with unopposed moderate or high dose oestrogen therapy was
higher than when compared with placebo treatment and women
were more likely not to adhere to their treatment regimen. The
distinction between regular and irregular bleeding is difficult since
scheduled bleeding is expected under sequential O + P therapy.
Further, women are likely to withdraw from a trial before com-
pletion if they are unhappy with unscheduled and unpredicted
bleeding, which may lead to an underestimation of the rate. The
distinction in the review between unscheduled bleeding occurring
within 6 months and after six months of treatment was arbitrary
and assessment in the latter group may have been measured at dif-
ferent times during treatment, for example, at seven months, 12
months or 24 months. Nevertheless, the included trials carefully
distinguished between scheduled and unscheduled bleeding where
these outcomes were measured. Sensitivity analysis also permitted
a more robust assessment when a high proportion of the group
withdrew from treatment. Bleeding at different time intervals af-
ter the initiation of treatment will be more precisely measured in
the coming review on comparative dosage trials of oestrogen and
progestogen.
The addition of progestogen to oestrogen replacement therapy in
women with intact uteri significantly prevented the development
of endometrial hyperplasia. The prevention of endometrial hyper-
plasia seemed to be related to type, duration and dose of progesto-
gen administered. Sequential O + P therapy, with the progesto-
gen administered for 12 days or more appeared to be more effec-
tive than shorter courses of progestogen although these regimens
were not directly compared. The duration of progestogen in the
included studies in this review ranged from 11 to 14 days and in
one study the progestogen was given in the first 12 days of the oe-
strogen regimen rather than during the latter part of the oestrogen
regimen (imitating the second half of the menstrual cycle). The
requirement that doses of progestogen in sequential therapy need
to be given for at least 10 days is confirmed by a large case-control
study (Pike 1997).
Irregular bleeding occurredmore frequentlywith continuous com-
bined O + P therapy when compared with unopposed oestrogen
therapy but was less likely under sequential O + P therapy when
compared with unopposed oestrogen therapy. There is good evi-
dence that this occurrence of irregular bleeding and spotting un-
der continuous combined therapy persists and gradually decreases
only within the first year after initiation of treatment and most
women have achieved amenorrhoea by 12 months (MacLennan
1993). Further investigation for irregular bleeding such as hys-
teroscopy and endometrial biopsy should be considered if irreg-
ular bleeding persists beyond 12 months of treatment. Concern
about bleeding on HRT is a major focus of women considering
treatment (MacLennan 1992; Whitehead 1990; Rozenberg 1996)
and counseling is required to elicit good compliance.
Unscheduled biopsies were performed more frequently in women
with unopposed oestrogen treatment regardless of type of O + P
treatment probably because of concern about endometrial stim-
ulation. Women were less likely to adhere to their unopposed O
treatment regimen when compared with O + P therapy either con-
tinuous or sequential.
Risk of endometrial hyperplasia or cancer was not significantly in-
creased by O + P regimens when compared with placebo although
endometrial cancer is a rare event and an adequate assessment of
this risk is unlikely to be made within the context of the limited
time frame of the trials included in this review (maximum three
years). Higher rates of endometrial hyperplasia after 24 months
of treatment in the sequential O + P group did not persist under
sensitivity analysis after the exclusion of poorer quality studies.
This finding clarifies the contradictory results of a recent meta-
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analysis of case control and cohort studies (Grady 1995). This
meta-analysis reported that in three cohort studies and one RCT
there was a decreased risk of endometrial cancer in users of oe-
strogen plus progestogen compared to non users but each of three
case control studies reported a non-significant small increase in en-
dometrial cancer risk associated with combination hormone use.
Irregular bleeding, however, was more likely under continuous
combined O + P therapy but not sequential O + P therapy when
compared with placebo although adherence to therapy did not
differ between continuous combined O + P therapy and placebo
treatment groups. Nevertheless, women were more likely not to
adhere to therapy when under sequential O + P treatment than
under placebo treatment.
Comparison of the type of progestogen regimen, continuous
combined versus sequential, suggested that after 36 months of
treatment endometrial hyperplasia was more likely under se-
quential treatment. There appeared to be an increasing duration
of treatment-response effect. Although this result was based on
only one study and should be treated with caution, two non-
randomised studies suggested that theremay be a higher rate of hy-
perplasia with sequential therapy (Sturdee 1994; Beresford 1997).
In most cases, the dose of progestogen used in the sequential regi-
mens is higher than the dose used in combined continuous treat-
ment. The daily exposure to any progestogen is obviously impor-
tant in preventing endometrial hyperplasia over a long period.
This evidence is critical given the long periods of time over which
women may take hormone replacement therapy.
Comparison of the long cycle sequential therapy (progestogen
given once every threemonths) with short cycle sequential therapy
(progestogen given once a month) was mostly based on one study
which was discontinued because of increased rates of hyperplasia
in the long cycle treatment group. Their finding was not con-
firmed by one small study (Heikkinen 1997) and results from a
prospective but non-randomised trial (Hirvonen 1995) show that
further research is urgently needed in this area.
This review has compared oestrogen only regimens and both com-
bined continuous and sequential oestrogen plus progestogen regi-
mens but has not been able to adequately determine the best dose,
duration and regimen of progestogen required to minimise the
proliferative effect of unopposed oestrogen on the endometrium
and prevent non adherence to treatment by keeping irregular
bleeding to a minimum.
R E V I E W E R S ’ C O N C L U S I O N S
Implications for practice
The evidence that unopposed oestrogen therapy increases the risk
of endometrial hyperplasia is consistently associated with the du-
ration and strength of dose. Irregular bleeding and consequent
treatment adherence problems may also result.
The addition of oral progestogens administered either cyclically
or continuously for endometrial protection should be considered
in women with an intact uterus. Endometrial hyperplasia may be
less likely under a continuous combined regimen than a sequen-
tial regimen, in particular with long durations of therapy. Regular
withdrawal bleeding is expected with a sequential regimen of O
+ P but women appear to experience less irregular bleeding than
with a continuous O + P regimen. Irregular or unscheduled bleed-
ing in the first year of continuous O + P therapy does not need
investigation but endometrial biopsy and hysteroscopy could be
considered after this time.
In current practice, sequential regimens are often recommended as
initial HRT for perimenopausal women, while women who have
not menstruated for more than 1 year are recommended to com-
mence on continuous regimens. These results should also be ap-
plied in the context of improvement of menopausal symptoms and
also long term benefits of various regimens of hormone replace-
ment therapy together with other adverse effects such as breast
tenderness, abdominal cramps, weight gain and mood swings.
In women who cannot tolerate or use progestogens, unopposed
oestrogen therapy can be considered, but follow up should include
long term annual endometrial assessment.
Implications for research
Although this review has compared unopposed oestrogen, com-
bined continuous and sequential regimens of O + P with each
other and placebo, it was not within the scope of the review to de-
termine the exact type, dose and duration of progestogen therapy
necessary to prevent endometrial stimulation without causing the
unwanted adverse effect of irregular bleeding. Another Cochrane
systematic review is planned to assess the effect that type, dose and
duration of progestogen use has on endometrial stimulation and
measure relative adherence to treatment and frequency of irregular
bleeding. This review will be more useful if treatment is assessed
over a prolonged period, for example, ten to twenty years.
The suggestion that combined continuous oestrogen-progestogen
therapy is more protective in the prevention of endometrial stim-
ulation than the sequential regimens should also be investigated
further.
The suggestion that short cycle sequential oestrogen-progestogen
therapy is more protective of the endometrium than long cycle
sequential oestrogen-progestogen therapy (progestogen adminis-
tered once every three months) should also be investigated further.
Progestogens administered via other routes, for example, as a nasal
spray or cream, by intramuscular injection and via an intrauterine
device are not in widespread use but should be evaluated thor-
oughly for efficacy, safety and acceptability as alternative methods
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of progestogen administration to be used in combination with oe-
strogen.
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T A B L E S
Characteristics of included studies
Study Blumel 1994
Methods Randomisation method not stated.
Single centre, parallel group design with double blinding.
Number of patients randomised: n=50.
Number of withdrawals: n=2 (lost to follow up from the placebo group).
No power calculation given and analysis not by intention to treat.
Source of funding not reported.
Participants Patients with menopausal symptoms, mean ages 51 and 53.5 years, recruited from climacteric clinic at the
Barros Luco-Trudeau Hospital in Chile.
Inclusion criteria: amenorrhoea for 6 months, FSH>40mUI/ml and plasma estradiol<50pg/ml.
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Characteristics of included studies (Continued )
Exclusion criteria: chronic illness, hormone dependant malignancies, use of oestrogen, progesterone or med-
ications that could modify the lipid profile within the last 6 months.
Interventions Treatment: Oestradiol valerate (EV) 2mg + medroxyprogesterone acetate (MPA) 2.5mg (continuous)
Control: Placebo
Duration: 6 months
Outcomes Bleeding patterns at 6 months follow up
Notes Publication (in Spanish) translated by Christine Aguilar, San Antonio Cochrane Centre.
Allocation concealment B
Study Byrjalsen 1992
Methods Randomisation method by sealed, opaque, sequentially numbered identical envelopes.
Single centre, parallel group design with double blinding.
Number of patients randomised: n=50.
Number of withdrawals: n=7 (1 from the placebo group because of illness unrelated to treatment and 6 from
the treatment group, 3 because of bleeding, 1 oedema and 2 because of lack of time).
No power calculation reported and analysis not by intention to treat.
Source of funding: antiserum supplied by Schering AG, Germany.
Participants Postmenopausal patients fromDenmark (clinic not stated), aged 45 to 57 years, who had undergone a natural
menopause 6 months to 3 years previously.
Exclusion criteria: past or present diseases or use of medication known to influence the lipid metabolism or
body composition, clinical or laboratory evidence of conditions that could influence the parameters to be
studied or contraindicate the trial medication.
Interventions Treatment: EV 2mg + Cyproterone acetate (CPA) 1mg 1 tablet daily
Control: Placebo 1 tablet daily
Duration: 2 years
Outcomes Frequency of hyperplasia
Irregular bleeding within the first three months
Irregular bleeding at 18 months after starting treatment
Non adherence to treatment
Notes Author contacted with queries about data and reply received.
Allocation concealment A
Study CHART 1996
Methods Randomised, double blind, placebo controlled, multicentre study.
Method of randomisation and allocation concealment: randomisation code prepared by Biometrics Depart-
ment in blocks of 9 with computer generated random numbers.
Number of patients randomised: n=1265
Number of withdrawals: n=570 (at 2 years) based on losses to follow up and stopping rule. Excluding the
10mcg EE2 group (treatment terminated due to high incidence of endometrial hyperplasia), 73% of subjects
completed the study.
Power calculation for sample size reported but analysis not by intention to treat.
Source of funding: Parke-Davis Pharmaceutical Research.
Participants Country: USA (65 study centres participated).
Participants: women aged 40 years or older who had undergone spontaneous menopause within the last five
years and who had an intact uterus.
Inclusion criteria: Healthy volunteers; FSH greater or equal to 40IU/L; estradiol less than or equal to 73
pmol/L; atrophic endometrium; no major illnesses.
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Characteristics of included studies (Continued )
Exclusion criteria: Baseline vaginal bleeding; baseline mammography suggestive of malignant disease; chronic
use of medications that affect bone calcium metabolism or significant vasomotor symptoms that required
medical treatment.
No participant was to have taken oral or transdermal oestrogen replacement therapy for 6 months prior to
randomisation.
Interventions Interventions:
1) 1mcg daily of oral ethinyl estradiol (EE2) plus 0.2mg of oral norethindrone acetate (NA) continuously
2) 2.5mcg daily of oral ethinyl estradiol (EE2) plus 0.5mg of oral norethindrone acetate (NA) continuously
3) 5mcg daily of oral ethinyl estradiol (EE2) plus 1mg of oral norethindrone acetate (NA) continuously
4) 10mcg daily of oral ethinyl estradiol (EE2) plus 1mg of oral norethindrone acetate (NA)
continuously
5) 1mcg daily of oral ethinyl estradiol (EE2) continuously
6) 2.5mcg daily of oral ethinyl estradiol (EE2) continuously
7) 5mcg daily of oral ethinyl estradiol (EE2) continuously
8) 10mcg daily of oral ethinyl estradiol (EE2) continuously
Control group: placebo
Duration: 2 years
Outcomes Endometrial biopsy at baseline and after 6,12,18 and 24 months of therapy.
Notes Based on priori stopping rules, subjects in Group 8 (10mcg daily of oral ethinyl estradiol (EE2) continuously)
were terminated from the study early owing to a high rate of hyperplasia for that treatment group.
Allocation concealment A
Study Ettinger 1992
Methods Randomisation method not stated.
Single centre, parallel group dose-ranging design with double blinding.
Number of patients randomised: not clear.
Number of patients analysed: n=63 (n=52 with intact uterus).
No power calculation reported and analysis not by intention to treat.
Source of funding: Mead Johnson Laboratories, Division of Bristol Myers.
Participants Country: USA.
Postmenopausal mostly white women, aged 40 to 58 years, recruited from advertisements and physician
referrals.
Inclusion criteria: Within 5 years of menopause (confirmed by bilateral oophorectomy or no menses for >=
6 months; oestrogen deficiency (confirmed by FSH>40 u/L); body weight within 20% of ideal for height
(Metropolitan Life Company Tables).
Exclusion criteria: Presence of diseases/conditions known to affect skeletal health such as thyroid/parathyroid
disorders or other disorders of calcium homeostasis; use of anticonvulsants or glucocorticoids; evidence of
renal, hepatic, cardiac or malignant diseases.
Interventions Treatment: (1) 0.5mg micronised 17B-oestradiol + calcium carbonate supplements daily on 23 of 28 days.
(2) 1.0mg micronised 17B-oestradiol + calcium carbonate supplements daily on 23 of 28 days
(3) 2.0mg micronised 17B-oestradiol + calcium carbonate supplements daily on 23 of 28 days
Control: Placebo + calcium carbonate supplements daily on 23 of 28 days
Duration: 18 months
Outcomes Frequency of hyperplasia (from endometrial biopsy)
Frequency of unexpected bleeding
Notes Eleven women (17.5%) had previous hysterectomy so above outcomes analysed in a subgroup of 52 women.
Primary objective of the study was to evaluate bone loss.
Allocation concealment B
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Characteristics of included studies (Continued )
Study Gelfand 1989
Methods Computerised random assignment controlled by pharmacist.
Single centre, parallel group design, double blinding.
Number of women randomised: n=173
Number of withdrawals: n=78 (n=24: 1 year of treatment not complete when study terminated and not
included in analysis; n=54: withdrew during the study for medical reasons but withdrawals not comparable
between treatment groups (9.5%, 9%, 2% and 28% respectively))
No power calculation reported and no analysis by intention to treat
Source of funding: Ayerst, McKenna and Harrison
Participants Postmenopausal women aged 47 to 57 years recruited from Menopause Clinic in Montreal Canada.
Other inclusion criteria: No contraindication for HRT; moderate vasomotor menopausal symptoms; no
bleeding for a minimum of 6 months; normotensive, normolipidemic; within 20% of their accepted weight
for height.
Exclusion criteria: diabetes; thromboembolic disease; history of carcinoma, alcohol or drug abuse; other
chronic illness or treatment with chronic medication; ERT <6 months prior to study.
Interventions Treatment: 1) 0.625mg daily of oral conjugated equine estrogen (CEE) for 25 days of a 30 day cycle, plus
placebo
2) 0.625mg daily of oral conjugated equine estrogen (CEE) for 25 days of a 30 day cycle, plus 5mg oral
medroxyprogesterone acetate added to the last 11 days of the CEE cycle
3) 1.25mg daily of oral conjugated equine estrogen (CEE) for 25 days of a 30 day cycle, plus placebo
4) 1.25mg daily of oral conjugated equine estrogen (CEE) for 25 days of a 30 day cycle, plus 5mg oral
medroxyprogesterone added to the last 11 days of the CEE cycle
Control: no control
Duration: 1 year
Outcomes Frequency of hyperplasia (endometrial biopsy at baseline, six and twelve months).
Irregular bleeding patterns at six and twelve months.
Non-adherence to therapy.
Notes
Allocation concealment A
Study Hagen 1982
Methods Randomisation by random sampling numbers but concealment of allocation not reported.
Single centre, parallel group design, placebo controlled with double blinding.
Number of patients randomised: n=119 (4 arms from of a much larger study).
Number of withdrawals: n=22 (5 excluded post randomisation for intercurrent disease (3 placebo and 2
treatment) and 17 losses to follow up: 14 for personal reasons (5 placebo and 9 treatment) and 3 moved from
the area).
No power calculation reported and analysis not by intention to treat.
Source of funding: Leo Pharmaceuticals, Medical Research Council, Direktor JacobMadsens og hustru Olga
Madsens Fund;DanishHospital Foundation forMedical Research;Novo Foundation; CCKlestrup og hustru
Henriette Klestrups Mindelegat; P Carl Petersens Fund; Nordisk Gjenforsikrings Selskabs Jubilaeumsfond;
Fabrikant Einar Willumsens Mindelegat; Grosserer AV Lykfeldt or hustrus Legat.
Participants Country: Denmark.
Women, aged 44 to 54 years, whose menstrual bleeding had stopped spontaneously within the last 1/2 to
3 years and who were not receiving treatment with gonadal hormones, thiazides or other drugs known to
influence calcium metabolism after the menopause.
Exclusion criteria: gynecological operation; elevated blood pressure (systolic above 170, diastolic above
105mmHg); abnormal blood chemistry; pathological cervical smear or any disease which contraindicated
the medications used in the trial.
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Characteristics of included studies (Continued )
Interventions Treatment: Trisequens forte (17B-oestradiol 4mg + estriol 2mg days 1-12, 17B-oestradiol 4mg + estriol 2mg
+ NETA 1mg days 13-22 and 17B-oestradiol 1mg + estriol 0.5mg days 23-28) (half of this group also took
bendroflumethiazide 5mg/day).
Control: Placebo (half of this group also took bendroflumethiazide).
Duration: 2 years
Outcomes Irregular bleeding patterns during treatment.
Notes All patients took 1 Sandoz calcium (500mg) tablet daily. The publication originally included 4 groups:
Trisequens + thiazide, Trisequens + placebo, Placebo + thiazide, Placebo + placebo. Since the mean changes
during the 2 years of treatment were almost identical in the 2 Trisequens groups and the 2 placebo groups,
these groups were combined for other evaluations. The study was part of a larger study with 315 women and
10 groups assessing bone loss.
Allocation concealment B
Study Harris 1991
Methods Randomisation method not reported but study medication concealed in identical bottles.
Multicentre (3 study sites), parallel group design, placebo controlled with double blinding.
Number of patients randomised: n=156.
Number of withdrawals: n=36 (28 lacked TBD values, 2 did not comply and 6 had baseline measurements
outside the time limits specified).
Power calculation for sample size performed and analysis by intention to treat for the outcomes reported in
this review.
Source of funding: Not reported.
Participants Country: USA
Postmenopausal patients with mean age 51 years recruited from 3 study sites.
Inclusion criteria: no use of sex hormones for previous 3 months; last normal period or bilateral oophorec-
tomy for benign conditions >2 months previously; FSH levels within the postmenopausal range; no con-
traindications to oestrogen therapy; no drug treatment (except sex steroids or calcium) for osteoporosis <1
year before entry into the study; resting supine BP <=160/90mm Hg at first visit; weight within 125% of
upper limit of Metropolitan Insurance Company reference weights; spinal bone mineral content measured
by tomography >=80mg/cm3 at first study visit.
Exclusion criteria: diseases or conditions that might affect bone or calcium metabolism or gastrointestinal
absorption; requirement for medication thatmight interfere with oestrogenmetabolism or efficacy or calcium
or bone metabolism; treatment with hypolipidemic agents or ketoconazole; use of fluoride for osteoporosis
at any time.
Interventions Treatment: (1) Oestrone sulphate 0.3mg + 2.5g calcium carbonate daily for 25 days, followed by 6 days
without treatment
(2) Oestrone sulphate 0.625mg + 2.5g calcium carbonate daily for 25 days + 6 days with no treatment
(3) Oestrone sulphate 1.25mg + 2.5g calcium carbonate daily for 25 days + 6 days with no treatment
Control: Placebo with same regimen
Duration: 2 years
Outcomes Frequency of hyperplasia at 2 years follow up
Frequency of irregular bleeding
Non adherence to therapy
Notes Author contacted for clarification of data relating to adherence to therapy and reviewer was referred to Abbott
Laboratories. Abbott Laboratories have not replied so adherence to therapy is not included in the review.
Allocation concealment B
Study Heikkinen 1997
Methods Randomisation method not stated.
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Characteristics of included studies (Continued )
Single centre, parallel group, blinding unclear.
Number of women randomised: n=78.
Number of women excluded: n=2.
No power calculation or intention to treat analysis.
Source of funding: Orion Corporation.
Participants Country: Finland
78 healthy women, aged 49 to 55, in early menopause recruited from the city of Oulu in Finland.
Inclusion criteria: 0.5-3 years postmenopausal (confirmed by FSH), without previous HRT,without con-
traindications for HRT.
Exclusion criteria: specified diseases.
Interventions Treatment:
(1) EV 2mg (day 1-21) + MPA 10mg (day 12-21)
(2) EV 2mg (day 1-84) + MPA 20mg (day 71-84)
Control: Placebo
Duration: 2 years
Outcomes Hyperplasia at 2 years
Irregular bleeding (data not published)
Adherence to treatment
Notes Published trial supplied by drug company, Orion Corporation, which manufactures Tridestra, a long cycle
sequential O + P treatment.
The primary outcomes of this study were effects of HRT and exercise on bone density, muscle strength and
lipid metabolism. Hyperplasia and adherence to treatment were secondary outcomes.
Allocation concealment B
Study Luciano 1993
Methods Randomisation method not stated.
Single centre, parallel group design with double blinding.
No of women randomised: n=36.
Number of withdrawals: n=7.
No power calculation performed and no intention to treat analysis
Source of funding: Upjohn (in part)
Participants Postmenopausal women were recruited from newspaper advertisements and letters to GPs in Farmington,
Connecticut.
Inclusion criteria: intact uterus, no contradindication to HRT, last menses at least one year prior, no HRT
for at least 6 months prior, oestradiol < 35 pg/mL and FSH < 50 mIU/mL.
No exclusion criteria stated.
Interventions Treatment 1: Continuous O + P (0.625mg CEE + 2.5mg MPA)
Treatment 2: Continuous O + P (0.625mg CEE + 5.0mg MPA)
Treatment 3: Sequential O + P (0.625mg CEE days 1-25 + 5.0mg MPA days 14-25)
Duration: 1 year
Outcomes Frequency of irregular bleeding
Notes
Allocation concealment B
Study MSG 1994
Methods Methods of randomisation and allocation: computer generated schedule with packaged coded medication.
Multicentre (99 sites), double-blind with parallel group design, placebo controlled.
Number of patients randomised: n=1724.
Number of withdrawals: n=255 after 1 year of follow up; n=339 after 2 years of follow up.
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Characteristics of included studies (Continued )
Power calculation for sample size performed but analysis not by intention to treat.
Source of funding: Wyeth-Ayerst Research.
Participants Countries: USA and Europe
Healthy women aged 45-65 years with an intact uterus were recruited from 99 sites.
Inclusion criteria: Last natural menstrual cycle at least 12 months before the baseline screening; FSH higher
than the lower limit for postmenopausal women for the given laboratory; no use of oestrogen- or progestogen-
containing medication for at least 2 weeks before the pre study screening.
Exclusion criteria: Any contraindication for oestrogen or progstagen use, or if they had used any oestrogen
containing medication within three months of entry; major medical illness, liver, kidney or diabetes; hy-
pertension, systolic blood pressure greater than 160 mmHg or diastolic pressure greater than 90 mmHg;
abnormal cervical cytology or endometrial hyperplasia at baseline biopsy.
Interventions Interventions:
1) 0.625 mg per day of conjugated equine estrogen (CEE), plus placebo
2) 0.625 mg per day of CEE plus 2.5 mg per day of medroxyprogesterone acetate (MPA) continuous
3) 0.625 mg per day of CEE plus 5 mg per day of medroxyprogesterone acetate (MPA) continuous
4) 0.625 mg per day of CEE plus 5 mg per day of (MPA) last 14 days of the cycle (days 15-28), plus placebo
(days 1-14)
5) 0.625 mg per day of CEE plus 10 mg per day of (MPA) last 14 days of the cycle (days 15-28), plus placebo
(days 1-14)
Control: No placebo group - Oestrogen only was compared with different regimens of oestrogen plus
progestagen.
Duration: one year (13 cycles)
Outcomes Frequency of hyperplasia and/or carcinoma (confirmed by endometrial biopsy) at 6 and 12 months (at the
end of cycles 6 and 13).
Frequency of irregular bleeding or spotting (number of cycles).
Notes If hyperplasia was confirmed, the patient was withdrawn from the study and given appropriate treatment.
Allocation concealment A
Study Marslew 1991
Methods Boxes of medication randomly numbered by independent person and distributed to participants successively.
Single centre, parallel group design, placebo controlled and blinding for measurements and calculations (not
participants).
Number of patients randomised: n=73.
Number of withdrawals: n=16 (5 from 1st treatment group: 3 because of adverse events, 1 because of lack
of time, 1 from illness unrelated to treatment; 7 from 2nd treatment group: 6 because of adverse events, 1
for personal reasons; 4 from placebo group: 1 for menopausal symptoms, 1 for personal reasons, 1 because
of lack of time and 1 moved).
No power calculation reported and analysis not by intention to treat.
Source of funding: Danish Medical Research Council; Organon.
Participants Country: Denmark
Healthy postmenopausal women, aged 45-54 years, with a menopausal duration of 6 months to 3 years and
no history of any disease or medication known to influence the variables studied, were recruited from the
Glostrup hospital area.
Exclusion criteria not reported.
Interventions Treatment: (1) 17B-oestradiol 1.5mg on days 1-12 and 17B-oestradiol 1.5mg + desogestrel 150ug on days
13-24
(2) EV 2mg on days 1-11 and EV 2mg + MPA 10mg on days 12-21
Control: Placebo
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Characteristics of included studies (Continued )
Duration: 2 years
Outcomes Frequency of irregular bleeding
Non-adherence to therapy
Notes This is Study B of 2 consecutive studies conducted in the same population in accordance with similar
protocols.
Allocation concealment A
Study Marslew 1992
Methods Randomisation and concealment of allocation identical to Marslew 1991 study.
Single centre, parallel group and placebo controlled design with single blinding (assessor, not participants).
Number of patients randomised: n=75.
Number of withdrawals: n=13 (6 from treatment 1 group: 3 because of persistent bleeding, 2 because of lack
of time and 1 because of oedema of the legs; 6 from treatment 2 group: 2 because of bleeding, 2 because of
headache, 1 from anxiety and 1 from unrelated illness; 1 from the placebo group because of thyrotoxicosis).
No power calculation reported and analysis not by intention to treat.
Source of funding: Danish Medical Council and Schering A/S.
Participants Country: Denmark
Healthy postmenopausal women, aged 45-54 years, with a menopausal duration of 6 months to 3 years and
no history of any disease or medication known to influence the variables studied, were recruited from the
Glostrup hospital area.
Exclusion criteria not reported.
Interventions Treatment: (1) Continuous EV 2mg + CPA 1mg
(2) Continuous EV 2mg + sequential levonorgestrel (LNG) 75ug (days 17-28)
Control: Continuous placebo
Duration: 2 years
Outcomes Frequency of irregular bleeding
Non-adherence to therapy
Notes This study is Study A of two consecutive studies conducted in the same population in accordance with similar
protocols.
Allocation concealment A
Study Mizunuma 1997
Methods Randomisation method not stated.
Single centre, parallel group design with no blinding.
Number of women randomised: n=52
Number of withdrawals: n=16
Power calculation for sample size performed but samples inadequate. Analysis not by intention to treat.
Source of funding: not stated.
Participants Country: Japan
52 women either with natural menopause or bilateral oophorectomy at least 1 year prior to study recruited
and the study conducted in the Department of Obstetrics and Gynaecology of a university hospital.
Inclusion criteria: regular menses, no hormonal treatment since menopause, no regular exercise, free of
hepatic, renal or other diseases with an effect on bone.
Exclusion criteria: not stated.
Interventions Treatment:
(1) CEE 0.625mg/day
(2) CEE 0.625mg + MPA 2.5mg/day
(3) CEE 0.3mg + MPA 2.5mg/day
Control: no treatment (data not given)
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Characteristics of included studies (Continued )
Duration: 2 years
Outcomes Irregular bleeding
Notes The primary outcome of this study was effect of treatment on bone loss and irregular bleeding was a secondary
outcome. The data for irregular bleeding were read off the graphs.
Allocation concealment B
Study Notelovitz 1996
Methods A single randomisation schedule was generated by the Department of Biometrics, Solvay Pharmaceuticals,
with 4-patient randomisation blocks of treatment distributed to each centre.
Multicentre, parallel group and placebo controlled design with double-blinding.
Number of patients randomised: n=280 (with intact uterus) of a total of 406.
Number of withdrawals: n=42 (before follow up endometrial biopsy).
Number of patients analysed: n=238 (54% of this group completed the study).
No power calculation reported but analysis by intention to treat.
Source of funding: Solvay Pharmaceuticals.
Participants Country: USA.
Healthy postmenopausal women with a uterus, aged 40-62, were recruited from 29 centres.
Inclusion criteria: natural or surgical menopause (final menstrual period or oophorectomy between 6 months
and 4 years prior to start of study; FSH>=50IU/L; non smokers; 45-54 years of age (>21 years if documented
bilateral oophorectomy; within 25% of ideal body weight (Metropolitan Height and Weight Tables).
Exclusion criteria: bone mineral density >= 2SD below normal peak for young adult women or evidence of
vertebral compression fracture on screening radiography; treatment with oestrogens or progestins within 8
weeks of enrolment; endometrial histology indicating either insufficient tissue in the presence of transvaginal
ultrasound endometrial thickness of >4 mmor proliferative, hyperplastic or secretory endometrium; previous
endometrial ablation; undiagnosed vaginal bleeding; oestrogen dependent cancers; abnormalities of Pap
smear or mammogram.
Interventions Treatment: (1) Esterified oestrogen (ESE) 0.3mg daily
(2) ESE 0.625mg daily
(3) ESE 1.25mg daily
Control: Placebo daily
Outcomes Frequency of endometrial hyperplasia at 6 and 12 months follow up.
Non-adherence to treatment.
Frequency of irregular bleeding.
Frequency of unscheduled endometrial biopsies (data not suitable for entry in the review)
Notes The outcomes reported in this review are only for the women with an intact uterus n=280 out of a total
n=406 in the study.
Allocation concealment A
Study Obel 1993
Methods Randomisation method and concealment of allocation not reported.
Single centre, parallel group and placebo controlled design with double blinding.
Number of patients randomised: n=151.
Number of withdrawals: n=22 (11 from treatment 1: 5 because of adverse events, 1 because of breast cancer,
5 for reasons unrelated to treatment; 5 from treatment 2: 3 because of adverse events, 2 because of carcinoma;
6 from placebo group: 1 because of adverse events, 1 because of anxiety, 1 for reasons unrelated to treatment).
No power calculation reported and analysis not by intention to treat.
Source of funding: Not reported.
Participants Country: Denmark
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Characteristics of included studies (Continued )
Volunteers with early menopause (last spontaneous vaginal bleeding >6 and <24 months earlier) and with
no use of HRT during preceding 24 months recruited from Frederiksborg County.
Exclusion criteria: previous or current oestrogen-dependent neoplasia; thromboembolic disease, liver or
pancreatic disease, diabetes mellitus, severe obesity, diseases with high or low bone turnover and medication
known to influence bone metabolism or provoke induction of liver enzymes.
Interventions Treatment: (1) Continuous E2 2mg + NETA 1mg (Kliogest) daily
(2) Sequential: Oestradiol (E2) 2mg (days 1-12), E2 2mg + norethisterone acetate (NETA) 1mg (days 13-22),
E2 1mg (days 23-28)
Control: Placebo
Duration: 2 years
Outcomes Frequency of endometrial hyperplasia and/or carcinoma at 2 years
Frequency of irregular bleeding
Non-adherence to therapy
Notes Some of the data was read off the graphs.
Allocation concealment B
Study PEPI 1995
Methods Methods of randomisation and allocation: computer generated.
Treatment group assignment was stratified by clinical center and uterine status (hysterectomy status).
Multicentre (7 clinical centres), parallel group, placebo controlled design with double blinding.
Number of patients randomised: n=596
Number of patients analysed: n=596 (no exclusions post randomisation).
Power calculation for sample size performed and analysis by intention to treat.
Source of funding: Wyeth-Ayerst Laboratories.
Participants Country: USA
875 healthy postmenopausal volunteers (596 with a uterus, 279 without a uterus), aged 45-65 years (average
56.2 years) were recruited via a national mass media campaign.
Inclusion criteria: good health; willing to accept random assignment to a hormone therapy or placebo;
cessation of menses for at least one year, but not more than 10 years prior to enrolment; surgically menopausal
at least 2 months after hysterectomy; FSH levels >= 40IU/L; normal atrophic endometrial biopsy and
mammography results at baseline.
Exclusion criteria : breast or endometrial cancer; any other cancer except non-melanomatous skin cancer di-
agnosed < 5 years before baseline; serious medical illness (myocardial infarction within six months, congestive
heart failure, stroke, transient ischaemic attack); severe menopausal symptoms; use of HRT within previous
2 months; hyper- or hypothyroidism; normal pelvic examination, papanicolaou test and endometrial biopsy.
Interventions Treatment: Participants randomised to equal numbers to one of the following oral treatments in 28 day
cycles:
1) 0.625mg per day of conjugated equine estrogen (CEE)
2) 0.625mg per day CEE + 10mg per day of Medroxyprogesterone acetate (MPA) for the first 12 days per
month (sequential)
3) 0.625mg per day CEE + 2.5mg per day of MPA (continuous)
4) 0.625mg per day CEE + 200mg per day of cyclic micronized progesterone for the first 12 days per month
(sequential)
Control: Placebo
Duration: 3 years
Outcomes Frequency of hyperplasia or carcinoma (confirmed by endometrial biopsy) annuallly (at 12, 24 and 36
months)
Frequency of unscheduled biopsies or dilatation and curettage
Non-adherence to therapy
b) Diary of symptoms, reports of vaginal bleeding, medication use and interim illnesses was reviewed.
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Characteristics of included studies (Continued )
Visits at three, six and twelve months first year, six months thereafter for a total of three years.
Notes 39 women were unblinded because of endometrial biopsy results classified as complex hyperplasia, atypia or
carcinoma. 32 of these were from the unopposed oestrogen group (group 1) , 3 were receiving placebo, and
4 were receiving one of the O + P regimens.
Allocation concealment A
Study Scandinavia 1996
Methods Randomisation method not given.
Multi-centre, parallel group design, blinding not clear.
Number of women randomised: n=240.
Number of exclusions: not given.
No indication given of power calculation or intention to treat analysis.
Source of funding: not given.
Participants Countries: Denmark, Norway and Sweden.
240 women recruited aged 45-65 years (mean 52 +/- 4 years) who had been postmenopausal for at least 1
year.
No other inclusion or exclusion criteria given.
Interventions Treatment 1: Oestradiol 2mg (day 1-78), oestradiol 1mg (day 79-84) + NET 1mg (day 69-78) (long cycle)
Treatment 2: Oestradiol 2mg (day 1-22), oestradiol 1mg (day 23-28) + NET 1mg (day 13-22) (short cycle)
Duration: 5 years (but study terminated early because of unsatisfactory safety profile.
Outcomes Endometrial hyperplasia or carcinoma.
Notes The details of this study are contained in published correspondence and authors contacted for additional
information but no reply received to date.
The studywas discontinued because of the unsatisfactory safety profile of the long-cycle hormone replacement
regimen.
Allocation concealment B
Study Williams 1990
Methods Randomisation method not stated.
Single centre, parallel group design with single blinding (assessors only).
No. of women randomised: n=77
No. of withdrawals: n=13
No power calculation performed and analysis not by intention to treat.
Source of funding not stated.
Participants Postmenopausal women, aged 37 to 59, were recruited from advertisements in a Cleveland newspaper.
Inclusion criteria: natural menopause (last menses between 12 and 60 months prior to the study), white or
oriental ethnic group, within 10% of ideal body weight, no hormonal therapy within the last 3 months,
nonsmoking.
Exclusion criteria: cancer, hypertension, diabetes, disease of liver, gall bladder disease, heart/vascular system
disease, alcoholism, corticosteroid therapy.
Interventions Treatment 1: Continuous O + P (20ug EE + 1.0mg NETA)
Treatment 2: Continuous O + P (10ug EE + 1.0mg NETA)
Treatment 3: Continuous O + P (10ug EE + 0.5mg NETA)
Treatment 4: Continuous O + P (5ug EE + 1.0mg NETA)
Treatment 5: Continuous O + P (5ug EE + 0.5mg NETA)
Treatment 6: Sequential O + P (0.625mg CEE days 1-25 + 10mg MPA days 16-25)
Outcomes Frequency of vaginal spotting at 3, 6, and 12 months
Non adherence to therapy
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Notes
Allocation concealment B
Characteristics of excluded studies
Study Reason for exclusion
Aoki 1990 This trial has published in abstract form and located by handsearching. No indication was given whether women
were randomised to treatment groups and attempts were made to contact the author for clarification but no reply
was received.
Campbell 1977 This trial is excluded because endometrial hyperplasia at baseline is not an exclusion criterion for entry into the
trial (exclusion criterion for this review is any contraindication to HRT).
Heytmanek 1990 This trial was published in abstract form and was located by handsearching. No indication was given whether
women were randomised to treatment groups and attempts were made to contact the author for clarification but
no reply was received.
Nachtigall 1979 Trial was based on 84 matched pairs that were randomised to treatment or placebo. However, participants were
hospitalised with long term chronic disease which is an exclusion criterion for this review.
Volpe 1986 This trial is excluded because endometrial hyperplasia at baseline is not an exclusion criterion for entry into the trial
(exclusion criterion for this review is any contraindication to HRT). The numbers in each arm of the trial are small
and the effects of treatment on the endometrium are evaluated by assessing the improvement in the endometrium
from baseline as a result of treatment.
G R A P H S
Comparison 01. LOW DOSE OESTROGEN VERSUS PLACEBO
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
Endometrial hyperplasia at 6
months
2 609 Peto Odds Ratio 95% CI 1.56 [0.22, 10.97]
Endometrial hyperplasia at 12
months
2 522 Peto Odds Ratio 95% CI 2.68 [0.69, 10.40]
Endometrial hyperplasia at 18-24
months
4 526 Peto Odds Ratio 95% CI 1.73 [0.66, 4.55]
Endometrial hyperplasia at 36
months
0 0 Peto Odds Ratio 95% CI Not estimable
Unscheduled biopsy or D & C 0 0 Peto Odds Ratio 95% CI Not estimable
Endometrial cancer 0 0 Peto Odds Ratio 95% CI Not estimable
Irregular bleeding patterns <
6mths from treatment
0 0 Peto Odds Ratio 95% CI Not estimable
Irregular bleeding patterns >=
6mths from treatment
3 237 Peto Odds Ratio 95% CI 0.87 [0.46, 1.64]
Non adherence to therapy 1 119 Peto Odds Ratio 95% CI 0.59 [0.25, 1.36]
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Comparison 02. MODERATE DOSE OESTROGEN VS PLACEBO
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
Endometrial hyperplasia at 6
months
1 119 Peto Odds Ratio 95% CI 5.40 [1.40, 20.91]
Endometrial hyperplasia at 12
months
2 357 Peto Odds Ratio 95% CI 8.29 [4.24, 16.21]
Endometrial hyperplasia at 18-24
months
4 445 Peto Odds Ratio 95% CI 9.58 [5.93, 15.46]
Endometrial hyperplasia at 36
months
1 238 Peto Odds Ratio 95% CI 15.99 [9.28, 27.54]
Unscheduled biopsy or D & C 1 238 Peto Odds Ratio 95% CI 19.94 [11.99, 33.14]
Endometrial cancer 1 238 Peto Odds Ratio 95% CI 0.14 [0.00, 6.82]
Irregular bleeding patterns <
6mths from treatment
0 0 Peto Odds Ratio 95% CI Not estimable
Irregular bleeding patterns >=
6mths from treatment
3 216 Peto Odds Ratio 95% CI 1.90 [1.05, 3.46]
Non adherence to therapy 2 357 Peto Odds Ratio 95% CI 3.57 [2.33, 5.47]
Comparison 03. HIGH DOSE OESTROGEN VS PLACEBO
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
Endometrial hyperplasia at 6
months
1 120 Peto Odds Ratio 95% CI 9.10 [3.62, 22.85]
Endometrial hyperplasia at 12
months
1 120 Peto Odds Ratio 95% CI 10.69 [4.55, 25.10]
Endometrial hyperplasia at 24
months
1 120 Peto Odds Ratio 95% CI 13.06 [5.88, 29.02]
Endometrial hyperplasia at 36
months
0 0 Peto Odds Ratio 95% CI Not estimable
Unscheduled biopsy or D & C 0 0 Peto Odds Ratio 95% CI Not estimable
Endometrial cancer 1 120 Peto Odds Ratio 95% CI Not estimable
Irregular bleeding patterns <
6mths from treatment
0 0 Peto Odds Ratio 95% CI Not estimable
Irregular bleeding patterns >=
6mths from treatment
1 106 Peto Odds Ratio 95% CI 6.01 [2.81, 12.86]
Non adherence to therapy 1 120 Peto Odds Ratio 95% CI 6.83 [3.35, 13.95]
Comparison 04. OESTROGEN VS OESTROGEN/PROGESTAGEN (continuous)
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
Endometrial hyperplasia at 6
months
5 1660 Peto Odds Ratio 95% CI 14.24 [6.41, 31.65]
Endometrial hyperplasia at 12
months
6 1680 Peto Odds Ratio 95% CI 14.98 [9.69, 23.16]
Endometrial hyperplasia at 24
months
5 734 Peto Odds Ratio 95% CI 14.53 [8.50, 24.84]
Endometrial hyperplasia at 36
months
1 239 Peto Odds Ratio 95% CI 17.07 [9.89, 29.44]
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Unscheduled biopsy or D & C 1 239 Peto Odds Ratio 95% CI 20.79 [12.51, 34.54]
Endometrial cancer 1 239 Peto Odds Ratio 95% CI Not estimable
Irregular bleeding patterns <=6
months after treatment
1 35 Peto Odds Ratio 95% CI 0.81 [0.19, 3.39]
Irregular bleeding patterns >6
months after treatment
1 35 Peto Odds Ratio 95% CI Not estimable
Number of cycles with irregular
bleeding at 12 months
1 11147 Peto Odds Ratio 95% CI 0.81 [0.73, 0.90]
Number of cycles with irregular
spotting at 12 months
1 11147 Peto Odds Ratio 95% CI 0.63 [0.56, 0.70]
Non adherence to therapy 1 239 Peto Odds Ratio 95% CI 6.02 [3.55, 10.21]
Comparison 05. OESTROGEN VS OESTROGEN + PROGESTAGEN (sequential)
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
Endometrial hyperplasia at 6
months
3 978 Peto Odds Ratio 95% CI 11.58 [5.48, 24.45]
Endometrial hyperplasia at 12
months
4 1284 Peto Odds Ratio 95% CI 15.15 [10.02, 22.91]
Endometrial hyperplasia at 24
months
1 357 Peto Odds Ratio 95% CI 19.83 [11.06, 35.55]
Endometrial hyperplasia at 36
months
1 357 Peto Odds Ratio 95% CI 22.56 [13.49, 37.71]
Unscheduled biopsy or D & C 1 357 Peto Odds Ratio 95% CI 20.50 [13.01, 32.32]
Endometrial cancer 2 1189 Peto Odds Ratio 95% CI 2.04 [0.11, 38.10]
Irregular bleeding patterns <6
months after Rx
0 0 Peto Odds Ratio 95% CI Not estimable
Irregular bleeding patterns >6
months after Rx
1 95 Peto Odds Ratio 95% CI 5.90 [2.54, 13.69]
Number of cycles of irregular
bleeding
1 11143 Peto Odds Ratio 95% CI 1.99 [1.75, 2.27]
Number of cycles of irregular
spotting
1 11143 Peto Odds Ratio 95% CI 1.00 [0.87, 1.14]
Non adherence to therapy 3 530 Peto Odds Ratio 95% CI 3.36 [2.21, 5.10]
Comparison 07. OESTROGEN + PROGESTOGEN (continuous) VS PLACEBO
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
Endometrial hyperplasia at 6
months
1 436 Peto Odds Ratio 95% CI Not estimable
Endometrial hyperplasia at 12
months
2 607 Peto Odds Ratio 95% CI Not estimable
Endometrial hyperplasia at 24
months
4 681 Peto Odds Ratio 95% CI 0.79 [0.06, 11.07]
Endometrial hyperplasia at 36
months
1 239 Peto Odds Ratio 95% CI 0.51 [0.05, 4.91]
Unscheduled biopsy or D & C 1 239 Peto Odds Ratio 95% CI 0.89 [0.37, 2.18]
Endometrial carcinoma 1 239 Peto Odds Ratio 95% CI 0.13 [0.00, 6.76]
Irregular bleeding patterns <6
months after treatment
2 139 Peto Odds Ratio 95% CI 6.37 [2.69, 15.08]
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Irregular bleeding patterns >=6
months after treatment
4 219 Peto Odds Ratio 95% CI 6.08 [2.70, 13.68]
Non adherence to therapy 4 440 Peto Odds Ratio 95% CI 1.27 [0.73, 2.21]
Comparison 08. OESTROGEN + PROGESTOGEN (sequential) vs PLACEBO
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
Endometrial hyperplasia at 12
months
2 406 Peto Odds Ratio 95% CI 3.03 [0.57, 16.05]
Endometrial hyperplasia at 24
months
3 495 Peto Odds Ratio 95% CI 4.00 [1.15, 13.95]
Endometrial hyperplasia at 36
months
1 357 Peto Odds Ratio 95% CI 2.43 [0.78, 7.55]
Unscheduled biopsy or D & C 1 357 Peto Odds Ratio 95% CI 1.49 [0.76, 2.92]
Endometrial cancer 1 357 Peto Odds Ratio 95% CI 0.05 [0.00, 3.18]
Irregular bleeding patterns <6
months after treatment
1 96 Peto Odds Ratio 95% CI 0.66 [0.11, 3.95]
Irregular bleeding patterns >=6
months after treatment
4 287 Peto Odds Ratio 95% CI 1.21 [0.51, 2.86]
Non adherence to therapy 4 276 Peto Odds Ratio 95% CI 3.47 [1.49, 8.09]
Comparison 10. OESTROGEN + PROGESTOGEN (continuous) VS OESTROGEN + PROGESTOGEN (sequen-
tial)
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
Endometrial hyperplasia at 6
months
1 1171 Peto Odds Ratio 95% CI 1.00 [0.06, 15.98]
Endometrial hyperplasia at 12
months
2 1460 Peto Odds Ratio 95% CI 0.45 [0.11, 1.87]
Endometrial hyperplasia at 24
months
2 442 Peto Odds Ratio 95% CI 0.38 [0.09, 1.68]
Endometrial hyperplasia at 36
months
1 358 Peto Odds Ratio 95% CI 0.30 [0.09, 0.97]
Endometrial cancer 2 1460 Peto Odds Ratio 95% CI 0.13 [0.00, 6.77]
Irregular bleeding patterns <6
months after treatment
2 154 Peto Odds Ratio 95% CI 1.46 [0.41, 5.26]
Irregular bleeding patterns >=6
months after treatment
4 215 Peto Odds Ratio 95% CI 0.41 [0.13, 1.31]
Number of cycles of irregular
bleeding
1 15012 Peto Odds Ratio 95% CI 2.29 [2.09, 2.52]
Number of cycles of irregular
spotting
1 15012 Peto Odds Ratio 95% CI 1.64 [1.49, 1.81]
Non adherence to therapy 5 612 Peto Odds Ratio 95% CI 0.70 [0.44, 1.09]
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Comparison 11. SEQUENTIAL OESTROGEN + PROGESTOGEN (1 month) VS SEQUENTIAL OESTROGEN
+ PROGESTOGEN (3 months)
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
Endometrial hyperplasia at 12
months
1 195 Peto Odds Ratio 95% CI 0.11 [0.03, 0.52]
Endometrial hyperplasia at 24
months
2 239 Peto Odds Ratio 95% CI 0.51 [0.15, 1.72]
Endometrial hyperplasia at 36
months
1 195 Peto Odds Ratio 95% CI 0.18 [0.06, 0.49]
Endometrial cancer 1 195 Peto Odds Ratio 95% CI 0.12 [0.00, 6.22]
Non adherence to therapy 1 52 Peto Odds Ratio 95% CI 0.38 [0.08, 1.83]
C O V E R S H E E T
Title Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and
irregular bleeding
Authors Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D
Contribution of author(s) Arpine Sarkis registered the title, prepared the protocol, selected trials for inclusion, assessed
quality and performed data extraction.
Ruth Jepson reviewed the protocol, performed searches, selected trials for inclusion, assessed
quality, and commented on the final draft of the review.
Cindy Farquhar reviewed the protocol, performed data extraction and commented on the
final draft of the review.
David Barlow provided comment on the protocol and the final draft of the review.
HelenRoberts assessed included trials for quality, performeddata extraction and commented
on the final draft of the review.
Anne Lethaby modified the protocol, performed searches, selected trials for inclusion, as-
sessed quality, performed data extraction, entered data, prepared the final review and incor-
porated suggested changes.
Issue protocol first published /
Date of most recent amendment 25 November 2003
Date of most recent
SUBSTANTIVE amendment
24 February 1999
What’s New Information not supplied by author
DOI 10.1002/14651858.CD000402
Cochrane Library number CD000402
Editorial group Cochrane Menstrual Disorders and Subfertility Group
Editorial group code HM-MENSTR
29Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Copyright © 2004 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
G R A P H S A N D O T H E R T A B L E S
Comparison 11. Endometrial hyperplasia at 6 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 01 LOW DOSE OESTROGEN VERSUS PLACEBO
Outcome: 01 Endometrial hyperplasia at 6 months
Study Low dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 1-10 mcg ethinyl oestradiol (EE)
CHART 1996 5/397 0/93 75.3 3.47 [ 0.37, 32.75 ]
Subtotal (95% CI) 397 93 75.3 3.47 [ 0.37, 32.75 ]
Total events: 5 (Low dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=1.09 p=0.3
02 0.3mg esterified oestrogens (ESE)
Notelovitz 1996 0/59 1/60 24.7 0.14 [ 0.00, 6.94 ]
Subtotal (95% CI) 59 60 24.7 0.14 [ 0.00, 6.94 ]
Total events: 0 (Low dose O), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.99 p=0.3
Total (95% CI) 456 153 100.0 1.56 [ 0.22, 10.97 ]
Total events: 5 (Low dose O), 1 (Placebo)
Test for heterogeneity chi-square=1.96 df=1 p=0.16 I =49.0%
Test for overall effect z=0.45 p=0.7
0.001 0.01 0.1 1 10 100 1000
Favours O Favours placebo
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Comparison 11. Endometrial hyperplasia at 12 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 01 LOW DOSE OESTROGEN VERSUS PLACEBO
Outcome: 02 Endometrial hyperplasia at 12 months
Study Low dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 1-10mcg ethinyl oestradiol (EE)
CHART 1996 10/320 0/83 58.0 3.63 [ 0.77, 17.09 ]
Subtotal (95% CI) 320 83 58.0 3.63 [ 0.77, 17.09 ]
Total events: 10 (Low dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=1.63 p=0.1
02 0.3mg esterified oestrogens (ESE)
Notelovitz 1996 1/59 1/60 18.0 1.02 [ 0.06, 16.46 ]
Subtotal (95% CI) 59 60 18.0 1.02 [ 0.06, 16.46 ]
Total events: 1 (Low dose O), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.01 p=1
03 0.3-0.45 mg conjugated equine estrogen(CEE)
Pickar 2001 10/548 0/43 24.1 2.99 [ 0.27, 33.11 ]
Subtotal (95% CI) 548 43 24.1 2.99 [ 0.27, 33.11 ]
Total events: 10 (Low dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.89 p=0.4
Total (95% CI) 927 186 100.0 2.75 [ 0.85, 8.96 ]
Total events: 21 (Low dose O), 1 (Placebo)
Test for heterogeneity chi-square=0.62 df=2 p=0.73 I =0.0%
Test for overall effect z=1.68 p=0.09
0.001 0.01 0.1 1 10 100 1000
Favours O Favours placebo
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Comparison 11. Endometrial hyperplasia at 18-24 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 01 LOW DOSE OESTROGEN VERSUS PLACEBO
Outcome: 03 Endometrial hyperplasia at 18-24 months
Study Low dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 1-10mcg ethinyl oestradiol (EE)
CHART 1996 14/239 1/59 55.0 2.38 [ 0.65, 8.75 ]
Subtotal (95% CI) 239 59 55.0 2.38 [ 0.65, 8.75 ]
Total events: 14 (Low dose O), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=1.31 p=0.2
02 0.5mg micronised 17B oestradiol (E2)
Ettinger 1992 1/8 0/14 5.6 15.64 [ 0.27, 920.01 ]
Subtotal (95% CI) 8 14 5.6 15.64 [ 0.27, 920.01 ]
Total events: 1 (Low dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=1.32 p=0.2
03 0.3mg and 0.625mg oestrone sulphate
Harris 1991 4/63 2/24 27.4 0.74 [ 0.12, 4.66 ]
Subtotal (95% CI) 63 24 27.4 0.74 [ 0.12, 4.66 ]
Total events: 4 (Low dose O), 2 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.32 p=0.7
04 0.3mg esterified oestrogens (ESE)
Notelovitz 1996 1/59 1/60 12.0 1.02 [ 0.06, 16.46 ]
Subtotal (95% CI) 59 60 12.0 1.02 [ 0.06, 16.46 ]
Total events: 1 (Low dose O), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.01 p=1
Total (95% CI) 369 157 100.0 1.73 [ 0.66, 4.55 ]
Total events: 20 (Low dose O), 4 (Placebo)
Test for heterogeneity chi-square=2.32 df=3 p=0.51 I =0.0%
Test for overall effect z=1.12 p=0.3
0.001 0.01 0.1 1 10 100 1000
Favours O Favours placebo
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Comparison 11. Endometrial hyperplasia at 36 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 01 LOW DOSE OESTROGEN VERSUS PLACEBO
Outcome: 04 Endometrial hyperplasia at 36 months
Study Low dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Total (95% CI) 0 0 0.0 Not estimable
Total events: 0 (Low dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours O Favours placebo
Comparison 11. Unscheduled biopsy or D & C
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 01 LOW DOSE OESTROGEN VERSUS PLACEBO
Outcome: 05 Additional investigations (unscheduled biopsy)
Study Low dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Total (95% CI) 0 0 0.0 Not estimable
Total events: 0 (Low dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours O Favours placebo
Comparison 11. Endometrial cancer
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 01 LOW DOSE OESTROGEN VERSUS PLACEBO
Outcome: 06 Endometrial cancer
Study Low dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Total (95% CI) 0 0 0.0 Not estimable
Total events: 0 (Low dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours O Favours placebo
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Comparison 11. Irregular bleeding patterns < 6mths from treatment
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 01 LOW DOSE OESTROGEN VERSUS PLACEBO
Outcome: 07 Irregular bleeding patterns < 6mths from treatment
Study Low dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Total (95% CI) 0 0 0.0 Not estimable
Total events: 0 (Low dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours O Favours placebo
Comparison 11. Irregular bleeding patterns >= 6mths from treatment
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 01 LOW DOSE OESTROGEN VERSUS PLACEBO
Outcome: 08 Irregular bleeding patterns >= 6mths from treatment
Study Low dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
x Ettinger 1992 0/11 0/14 0.0 Not estimable
Harris 1991 12/73 9/35 39.7 0.56 [ 0.20, 1.53 ]
Notelovitz 1996 18/54 15/50 60.3 1.16 [ 0.51, 2.65 ]
Total (95% CI) 138 99 100.0 0.87 [ 0.46, 1.64 ]
Total events: 30 (Low dose O), 24 (Placebo)
Test for heterogeneity chi-square=1.23 df=1 p=0.27 I =18.8%
Test for overall effect z=0.43 p=0.7
0.1 0.2 0.5 1 2 5 10
Favours O Favours placebo
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Comparison 11. Non adherence to therapy
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 01 LOW DOSE OESTROGEN VERSUS PLACEBO
Outcome: 09 Non adherence to therapy
Study Low dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Notelovitz 1996 11/59 17/60 100.0 0.59 [ 0.25, 1.36 ]
Total (95% CI) 59 60 100.0 0.59 [ 0.25, 1.36 ]
Total events: 11 (Low dose O), 17 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=1.24 p=0.2
0.1 0.2 0.5 1 2 5 10
Favours O Favours placebo
Comparison 11. Endometrial hyperplasia at 6 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 02 MODERATE DOSE OESTROGEN VS PLACEBO
Outcome: 01 Endometrial hyperplasia at 6 months
Study Mod dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 0.625mg esterified oestrogens (ESE)
Notelovitz 1996 8/59 1/60 100.0 5.40 [ 1.40, 20.91 ]
Total (95% CI) 59 60 100.0 5.40 [ 1.40, 20.91 ]
Total events: 8 (Mod dose O), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=2.44 p=0.01
0.001 0.01 0.1 1 10 100 1000
Favours O Favours placebo
35Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Copyright © 2004 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Comparison 11. Endometrial hyperplasia at 12 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 02 MODERATE DOSE OESTROGEN VS PLACEBO
Outcome: 02 Endometrial hyperplasia at 12 months
Study Mod dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 0.625mg conjugated equine oestrogen (CEE)
PEPI 1995 25/119 0/119 52.8 9.26 [ 4.05, 21.16 ]
Pickar 2001 20/249 0/37 19.8 3.42 [ 0.89, 13.23 ]
Subtotal (95% CI) 368 156 72.6 7.06 [ 3.49, 14.29 ]
Total events: 45 (Mod dose O), 0 (Placebo)
Test for heterogeneity chi-square=1.51 df=1 p=0.22 I =33.9%
Test for overall effect z=5.43 p<0.00001
02 0.625mg esterified oestrogens (ESE)
Notelovitz 1996 12/59 1/60 27.4 6.70 [ 2.13, 21.11 ]
Subtotal (95% CI) 59 60 27.4 6.70 [ 2.13, 21.11 ]
Total events: 12 (Mod dose O), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=3.25 p=0.001
Total (95% CI) 427 216 100.0 6.96 [ 3.82, 12.69 ]
Total events: 57 (Mod dose O), 1 (Placebo)
Test for heterogeneity chi-square=1.52 df=2 p=0.47 I =0.0%
Test for overall effect z=6.33 p<0.00001
0.001 0.01 0.1 1 10 100 1000
Favours O Favours placebo
36Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Copyright © 2004 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Comparison 11. Endometrial hyperplasia at 18-24 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 02 MODERATE DOSE OESTROGEN VS PLACEBO
Outcome: 03 Endometrial hyperplasia at 18-24 months
Study Mod dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 0.625mg conjugated equine oestrogen (CEE)
PEPI 1995 54/119 0/119 62.6 13.15 [ 7.18, 24.08 ]
Subtotal (95% CI) 119 119 62.6 13.15 [ 7.18, 24.08 ]
Total events: 54 (Mod dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=8.34 p<0.00001
02 1.0mg and 2.0mg micronised 17B oestradiol (E2)
Ettinger 1992 4/20 0/14 5.3 6.49 [ 0.80, 52.37 ]
Subtotal (95% CI) 20 14 5.3 6.49 [ 0.80, 52.37 ]
Total events: 4 (Mod dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=1.75 p=0.08
03 1.25mg oestrone sulphate
Harris 1991 5/30 2/24 9.2 2.06 [ 0.42, 10.05 ]
Subtotal (95% CI) 30 24 9.2 2.06 [ 0.42, 10.05 ]
Total events: 5 (Mod dose O), 2 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.90 p=0.4
04 0.625mg esterified oestrogens (ESE)
Notelovitz 1996 17/59 1/60 23.0 8.14 [ 3.00, 22.10 ]
Subtotal (95% CI) 59 60 23.0 8.14 [ 3.00, 22.10 ]
Total events: 17 (Mod dose O), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=4.11 p=0.00004
Total (95% CI) 228 217 100.0 9.58 [ 5.93, 15.46 ]
Total events: 80 (Mod dose O), 3 (Placebo)
Test for heterogeneity chi-square=4.90 df=3 p=0.18 I =38.7%
Test for overall effect z=9.25 p<0.00001
0.001 0.01 0.1 1 10 100 1000
Favours O Favours placebo
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Comparison 11. Endometrial hyperplasia at 36 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 02 MODERATE DOSE OESTROGEN VS PLACEBO
Outcome: 04 Endometrial hyperplasia at 36 months
Study Mod dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 0.625mg conjugated equine oestrogen (CEE)
PEPI 1995 74/119 2/119 100.0 15.99 [ 9.28, 27.54 ]
Total (95% CI) 119 119 100.0 15.99 [ 9.28, 27.54 ]
Total events: 74 (Mod dose O), 2 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=9.99 p<0.00001
0.001 0.01 0.1 1 10 100 1000
Favours O Favours placebo
Comparison 11. Unscheduled biopsy or D & C
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 02 MODERATE DOSE OESTROGEN VS PLACEBO
Outcome: 05 Additional investigations (unscheduled biopsy)
Study Mod dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
PEPI 1995 100/119 11/119 100.0 19.94 [ 11.99, 33.14 ]
Total (95% CI) 119 119 100.0 19.94 [ 11.99, 33.14 ]
Total events: 100 (Mod dose O), 11 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=11.54 p<0.00001
0.001 0.01 0.1 1 10 100 1000
Favours O Favours placebo
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Comparison 11. Endometrial cancer
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 02 MODERATE DOSE OESTROGEN VS PLACEBO
Outcome: 06 Endometrial cancer
Study Mod dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
PEPI 1995 0/119 1/119 100.0 0.14 [ 0.00, 6.82 ]
Total (95% CI) 119 119 100.0 0.14 [ 0.00, 6.82 ]
Total events: 0 (Mod dose O), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=1.00 p=0.3
0.001 0.01 0.1 1 10 100 1000
Favours O Favours placebo
Comparison 11. Irregular bleeding patterns < 6mths from treatment
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 02 MODERATE DOSE OESTROGEN VS PLACEBO
Outcome: 07 Irregular bleeding patterns < 6mths from treatment
Study Mod dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Total (95% CI) 0 0 0.0 Not estimable
Total events: 0 (Mod dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours O Favours placebo
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Comparison 11. Irregular bleeding patterns >= 6mths from treatment
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 02 MODERATE DOSE OESTROGEN VS PLACEBO
Outcome: 08 Irregular bleeding patterns >= 6mths from treatment
Study Mod dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Ettinger 1992 4/27 0/14 7.7 5.16 [ 0.60, 44.27 ]
Harris 1991 12/36 9/35 34.8 1.43 [ 0.52, 3.95 ]
Notelovitz 1996 25/54 15/50 57.5 1.98 [ 0.90, 4.34 ]
Total (95% CI) 117 99 100.0 1.90 [ 1.05, 3.46 ]
Total events: 41 (Mod dose O), 24 (Placebo)
Test for heterogeneity chi-square=1.14 df=2 p=0.57 I =0.0%
Test for overall effect z=2.12 p=0.03
0.1 0.2 0.5 1 2 5 10
Favours O Favours placebo
Comparison 11. Non adherence to therapy
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 02 MODERATE DOSE OESTROGEN VS PLACEBO
Outcome: 09 Mean number of excess bleeding episodes(36 months)
Study CEE placebo Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 conjugated equine estrogen 0.625 mg
PEPI 2002 53 3.60 (3.30) 91 1.50 (1.00) 100.0 2.10 [ 1.19, 3.01 ]
Total (95% CI) 53 91 100.0 2.10 [ 1.19, 3.01 ]
Test for heterogeneity: not applicable
Test for overall effect z=4.51 p<0.00001
-10.0 -5.0 0 5.0 10.0
Favours CEE Favours placebo
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Comparison 11. Endometrial hyperplasia at 6 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 03 HIGH DOSE OESTROGEN VS PLACEBO
Outcome: 01 Endometrial hyperplasia at 6 months
Study High dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 1.25mg ESE
Notelovitz 1996 21/60 1/60 100.0 9.10 [ 3.62, 22.84 ]
Total (95% CI) 60 60 100.0 9.10 [ 3.62, 22.84 ]
Total events: 21 (High dose O), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=4.70 p<0.00001
0.001 0.01 0.1 1 10 100 1000
Favours O Favours Placebo
Comparison 11. Endometrial hyperplasia at 12 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 03 HIGH DOSE OESTROGEN VS PLACEBO
Outcome: 02 Endometrial hyperplasia at 12 months
Study High dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 1.25mg ESE
Notelovitz 1996 26/60 1/60 100.0 10.69 [ 4.55, 25.10 ]
Total (95% CI) 60 60 100.0 10.69 [ 4.55, 25.10 ]
Total events: 26 (High dose O), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=5.44 p<0.00001
0.001 0.01 0.1 1 10 100 1000
Favours O Favours Placebo
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Comparison 11. Endometrial hyperplasia at 24 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 03 HIGH DOSE OESTROGEN VS PLACEBO
Outcome: 03 Endometrial hyperplasia at 24 months
Study High dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 1.25mg ESE
Notelovitz 1996 32/60 1/60 100.0 13.06 [ 5.88, 29.02 ]
Total (95% CI) 60 60 100.0 13.06 [ 5.88, 29.02 ]
Total events: 32 (High dose O), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=6.31 p<0.00001
0.001 0.01 0.1 1 10 100 1000
Favours O Favours Placebo
Comparison 11. Endometrial hyperplasia at 36 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 03 HIGH DOSE OESTROGEN VS PLACEBO
Outcome: 04 Endometrial hyperplasia at 36 months
Study High dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 1.25mg ESE
Total (95% CI) 0 0 0.0 Not estimable
Total events: 0 (High dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.001 0.01 0.1 1 10 100 1000
Favours O Favours Placebo
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Comparison 11. Unscheduled biopsy or D & C
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 03 HIGH DOSE OESTROGEN VS PLACEBO
Outcome: 05 Additional investigations (unscheduled biopsy)
Study High dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Total (95% CI) 0 0 0.0 Not estimable
Total events: 0 (High dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours O Favours Placebo
Comparison 11. Endometrial cancer
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 03 HIGH DOSE OESTROGEN VS PLACEBO
Outcome: 06 Endometrial cancer
Study High dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
x Notelovitz 1996 0/60 0/60 0.0 Not estimable
Total (95% CI) 60 60 0.0 Not estimable
Total events: 0 (High dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours O Favours Placebo
Comparison 11. Irregular bleeding patterns < 6mths from treatment
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 03 HIGH DOSE OESTROGEN VS PLACEBO
Outcome: 07 Irregular bleeding patterns < 6mths from treatment
Study High dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Total (95% CI) 0 0 0.0 Not estimable
Total events: 0 (High dose O), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours O Favours Placebo
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Comparison 11. Irregular bleeding patterns >= 6mths from treatment
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 03 HIGH DOSE OESTROGEN VS PLACEBO
Outcome: 08 Irregular bleeding patterns >= 6mths from treatment
Study High dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Notelovitz 1996 42/56 15/50 100.0 6.01 [ 2.81, 12.86 ]
Total (95% CI) 56 50 100.0 6.01 [ 2.81, 12.86 ]
Total events: 42 (High dose O), 15 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=4.62 p<0.00001
0.1 0.2 0.5 1 2 5 10
Favours O Favours Placebo
Comparison 11. Non adherence to therapy
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 03 HIGH DOSE OESTROGEN VS PLACEBO
Outcome: 09 Non adherence to therapy
Study High dose O Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Notelovitz 1996 46/60 17/60 100.0 6.83 [ 3.35, 13.95 ]
Total (95% CI) 60 60 100.0 6.83 [ 3.35, 13.95 ]
Total events: 46 (High dose O), 17 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=5.28 p<0.00001
0.1 0.2 0.5 1 2 5 10
Favours O Favours Placebo
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Comparison 11. Endometrial hyperplasia at 6 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 04 OESTROGEN VS OESTROGEN/PROGESTAGEN (continuous)
Outcome: 01 Endometrial hyperplasia at 6 months
Study Oestrogen Oest + Prog (cont) Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 1ug EE vs 1ug EE + 0.2mg NET
x CHART 1996 0/87 0/84 0.0 Not estimable
Subtotal (95% CI) 87 84 0.0 Not estimable
Total events: 0 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 2.5ug EE vs 2.5ug EE + 0.5mg NET
x CHART 1996 0/140 0/75 0.0 Not estimable
Subtotal (95% CI) 140 75 0.0 Not estimable
Total events: 0 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 5.0ug EE vs 5.0ug EE + 1.0mg NET
x CHART 1996 0/107 0/92 0.0 Not estimable
Subtotal (95% CI) 107 92 0.0 Not estimable
Total events: 0 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect: not applicable
04 10ug EE vs 10ug EE + 1.0mg NET
CHART 1996 5/99 0/92 20.3 7.18 [ 1.22, 42.26 ]
Subtotal (95% CI) 99 92 20.3 7.18 [ 1.22, 42.26 ]
Total events: 5 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=2.18 p=0.03
05 CEE 0.625mg vs CEE 0.625mg + MPA 2.5 or 5mg
MSG 1994 21/298 1/586 79.7 16.95 [ 6.93, 41.47 ]
Subtotal (95% CI) 298 586 79.7 16.95 [ 6.93, 41.47 ]
Total events: 21 (Oestrogen), 1 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=6.20 p<0.00001
Total (95% CI) 731 929 100.0 14.24 [ 6.41, 31.65 ]
Total events: 26 (Oestrogen), 1 (Oest + Prog (cont))
Test for heterogeneity chi-square=0.72 df=1 p=0.40 I =0.0%
Test for overall effect z=6.52 p<0.00001
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Comparison 11. Endometrial hyperplasia at 12 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 04 OESTROGEN VS OESTROGEN/PROGESTAGEN (continuous)
Outcome: 02 Endometrial hyperplasia at 12 months
Study Oestrogen Oest + Prog (cont) Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 1ug EE vs 1ug EE + 0.2mg NET
x CHART 1996 0/75 0/80 0.0 Not estimable
Subtotal (95% CI) 75 80 0.0 Not estimable
Total events: 0 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 2.5ug EE vs 2.5ug EE + 0.5mg NET
x CHART 1996 0/90 0/69 0.0 Not estimable
Subtotal (95% CI) 90 69 0.0 Not estimable
Total events: 0 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 5.0ug EE vs 5.0ug EE + 1.0mg NET
CHART 1996 1/94 0/65 0.7 5.43 [ 0.10, 292.45 ]
Subtotal (95% CI) 94 65 0.7 5.43 [ 0.10, 292.45 ]
Total events: 1 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=0.83 p=0.4
04 10ug EE vs 10ug EE + 1.0mg NET
CHART 1996 9/61 0/71 6.0 10.02 [ 2.59, 38.75 ]
Subtotal (95% CI) 61 71 6.0 10.02 [ 2.59, 38.75 ]
Total events: 9 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=3.34 p=0.0008
05 E2 1mg/NETA 0.1 mg
Kurman 2000 12/82 2/249 7.1 30.09 [ 8.72, 103.77 ]
Subtotal (95% CI) 82 249 7.1 30.09 [ 8.72, 103.77 ]
Total events: 12 (Oestrogen), 2 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=5.39 p<0.00001
06 E2 1 mg/NETA 0.25 mg
Kurman 2000 12/82 1/251 6.6 43.96 [ 12.16, 158.93 ]
Subtotal (95% CI) 82 251 6.6 43.96 [ 12.16, 158.93 ]
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(. . . Continued)
Study Oestrogen Oest + Prog (cont) Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Total events: 12 (Oestrogen), 1 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=5.77 p<0.00001
07 E2 1 mg/NETA 0.5 mg
Kurman 2000 12/83 1/241 6.8 37.90 [ 10.65, 134.84 ]
Subtotal (95% CI) 83 241 6.8 37.90 [ 10.65, 134.84 ]
Total events: 12 (Oestrogen), 1 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=5.61 p<0.00001
08 CEE 0.3 mg vs CEE(0.3mg-0.625mg) /MPA(1.5mg-2.5mg)
Pickar 2001 1/269 1/365 1.4 1.36 [ 0.08, 22.57 ]
Subtotal (95% CI) 269 365 1.4 1.36 [ 0.08, 22.57 ]
Total events: 1 (Oestrogen), 1 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=0.22 p=0.8
09 CEE 0.45 mg vs CEE (0.3mg-0.625mg)/MPA (1.5 mg-2.5 mg)
Pickar 2001 9/279 1/365 6.9 6.88 [ 1.95, 24.23 ]
Subtotal (95% CI) 279 365 6.9 6.88 [ 1.95, 24.23 ]
Total events: 9 (Oestrogen), 1 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=3.00 p=0.003
10 CEE 0.625 mg vs CEE(0.3 mg-0.625mg)/MPA(1.5 mg-2.5 mg)
Pickar 2001 20/249 0/365 13.3 12.74 [ 5.14, 31.55 ]
Subtotal (95% CI) 249 365 13.3 12.74 [ 5.14, 31.55 ]
Total events: 20 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=5.50 p<0.00001
11 CEE 0.625mg vs CEE 0.625mg + MPA 2.5 or 5mg
MSG 1994 57/283 2/553 35.1 20.33 [ 11.62, 35.55 ]
PEPI 1995 25/119 0/120 16.0 9.33 [ 4.08, 21.34 ]
Subtotal (95% CI) 402 673 51.1 15.92 [ 10.02, 25.30 ]
Total events: 82 (Oestrogen), 2 (Oest + Prog (cont))
Test for heterogeneity chi-square=2.34 df=1 p=0.13 I =57.2%
Test for overall effect z=11.71 p<0.00001
Total (95% CI) 1766 2794 100.0 16.16 [ 11.61, 22.50 ]
Total events: 158 (Oestrogen), 8 (Oest + Prog (cont))
Test for heterogeneity chi-square=13.15 df=9 p=0.16 I =31.6%
Test for overall effect z=16.47 p<0.00001
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Comparison 11. Endometrial hyperplasia at 24 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 04 OESTROGEN VS OESTROGEN/PROGESTAGEN (continuous)
Outcome: 03 Endometrial hyperplasia at 24 months
Study Oestrogen Oest + Prog (cont) Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 1ug EE vs 1ug EE + 0.2mg NET
CHART 1996 1/64 1/69 3.7 1.08 [ 0.07, 17.47 ]
Subtotal (95% CI) 64 69 3.7 1.08 [ 0.07, 17.47 ]
Total events: 1 (Oestrogen), 1 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=0.05 p=1
02 2.5ug EE vs 2.5ug EE + 0.5mg NET
CHART 1996 1/67 0/57 1.9 6.36 [ 0.12, 324.89 ]
Subtotal (95% CI) 67 57 1.9 6.36 [ 0.12, 324.89 ]
Total events: 1 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=0.92 p=0.4
03 5.0ug EE vs 5.0ug EE + 1.0mg NET
CHART 1996 2/90 0/65 3.6 5.66 [ 0.34, 94.75 ]
Subtotal (95% CI) 90 65 3.6 5.66 [ 0.34, 94.75 ]
Total events: 2 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=1.21 p=0.2
04 10ug EE vs 10ug EE + 1.0mg NET
CHART 1996 10/18 0/65 11.3 177.61 [ 36.08, 874.43 ]
Subtotal (95% CI) 18 65 11.3 177.61 [ 36.08, 874.43 ]
Total events: 10 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=6.37 p<0.00001
05 CEE 0.625mg vs CEE 0.625mg + MPA 2.5 or 5mg
PEPI 1995 54/119 1/120 79.5 12.23 [ 6.70, 22.31 ]
Subtotal (95% CI) 119 120 79.5 12.23 [ 6.70, 22.31 ]
Total events: 54 (Oestrogen), 1 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=8.16 p<0.00001
Total (95% CI) 358 376 100.0 14.53 [ 8.50, 24.84 ]
Total events: 68 (Oestrogen), 2 (Oest + Prog (cont))
Test for heterogeneity chi-square=13.74 df=4 p=0.008 I =70.9%
Test for overall effect z=9.79 p<0.00001
0.001 0.01 0.1 1 10 100 1000
Favours O Favours O + P
48Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Copyright © 2004 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Comparison 11. Endometrial hyperplasia at 36 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 04 OESTROGEN VS OESTROGEN/PROGESTAGEN (continuous)
Outcome: 04 Endometrial hyperplasia at 36 months
Study Oestrogen Oest + Prog (cont) Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 CEE 0.625mg vs CEE 0.625mg + MPA 2.5 or 5mg
PEPI 1995 74/119 1/120 100.0 17.07 [ 9.89, 29.44 ]
Total (95% CI) 119 120 100.0 17.07 [ 9.89, 29.44 ]
Total events: 74 (Oestrogen), 1 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=10.20 p<0.00001
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Comparison 11. Unscheduled biopsy or D & C
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 04 OESTROGEN VS OESTROGEN/PROGESTAGEN (continuous)
Outcome: 05 Additional investigations (unscheduled biopsy)
Study Oestrogen Oest + Prog (cont) Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
MSG 1994 100/119 10/120 100.0 20.79 [ 12.51, 34.54 ]
Total (95% CI) 119 120 100.0 20.79 [ 12.51, 34.54 ]
Total events: 100 (Oestrogen), 10 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=11.72 p<0.00001
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Comparison 11. Endometrial cancer
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 04 OESTROGEN VS OESTROGEN/PROGESTAGEN (continuous)
Outcome: 06 Endometrial cancer
Study Oestrogen Oest + Prog (cont) Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
x PEPI 1995 0/119 0/120 0.0 Not estimable
Total (95% CI) 119 120 0.0 Not estimable
Total events: 0 (Oestrogen), 0 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect: not applicable
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Comparison 11. Irregular bleeding patterns <=6 months after treatment
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 04 OESTROGEN VS OESTROGEN/PROGESTAGEN (continuous)
Outcome: 07 Irregular bleeding patterns <=6 months after treatment
Study Oestrogen Oest + Prog (cont) Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Mizunuma 1997 4/14 7/21 100.0 0.81 [ 0.19, 3.39 ]
Total (95% CI) 14 21 100.0 0.81 [ 0.19, 3.39 ]
Total events: 4 (Oestrogen), 7 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=0.29 p=0.8
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Comparison 11. Irregular bleeding patterns >6 months after treatment
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 04 OESTROGEN VS OESTROGEN/PROGESTAGEN (continuous)
Outcome: 08 Irregular bleeding at month 11
Study Oestrogen O + P Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
01 E2 1 mg vs E2 1 mg/NET 0.1 mg
Archer 1999 28/97 61/292 43.2 1.54 [ 0.91, 2.59 ]
Subtotal (95% CI) 97 292 43.2 1.54 [ 0.91, 2.59 ]
Total events: 28 (Oestrogen), 61 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=1.61 p=0.1
02 E2 1mg vs E2 1mg/NET 0.25 mg
Archer 1999 28/98 49/290 35.3 1.97 [ 1.15, 3.36 ]
Subtotal (95% CI) 98 290 35.3 1.97 [ 1.15, 3.36 ]
Total events: 28 (Oestrogen), 49 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=2.48 p=0.01
03 E2 1 mg vs E2 1mg/NET 0.5 mg
Archer 1999 28/98 30/290 21.6 3.47 [ 1.94, 6.18 ]
Subtotal (95% CI) 98 290 21.6 3.47 [ 1.94, 6.18 ]
Total events: 28 (Oestrogen), 30 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=4.21 p=0.00003
Total (95% CI) 293 872 100.0 2.11 [ 1.54, 2.88 ]
Total events: 84 (Oestrogen), 140 (O + P)
Test for heterogeneity chi-square=4.31 df=2 p=0.12 I =53.6%
Test for overall effect z=4.68 p<0.00001
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Comparison 11. Number of cycles with irregular bleeding at 12 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 04 OESTROGEN VS OESTROGEN/PROGESTAGEN (continuous)
Outcome: 09 Number of cycles with irregular bleeding within 12 months
Study Oestrogen Oest + Prog (cont) Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
MSG 1994 532/3639 1319/7508 100.0 0.81 [ 0.73, 0.90 ]
Total (95% CI) 3639 7508 100.0 0.81 [ 0.73, 0.90 ]
Total events: 532 (Oestrogen), 1319 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=3.92 p=0.00009
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Comparison 11. Number of cycles with irregular spotting at 12 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 04 OESTROGEN VS OESTROGEN/PROGESTAGEN (continuous)
Outcome: 10 Number of cycles with irregular spotting within 12 months
Study Oestrogen Oest + Prog (cont) Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
MSG 1994 358/3639 1151/7508 100.0 0.63 [ 0.56, 0.70 ]
Total (95% CI) 3639 7508 100.0 0.63 [ 0.56, 0.70 ]
Total events: 358 (Oestrogen), 1151 (Oest + Prog (cont))
Test for heterogeneity: not applicable
Test for overall effect z=7.95 p<0.00001
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Comparison 11. Non adherence to therapy
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 04 OESTROGEN VS OESTROGEN/PROGESTAGEN (continuous)
Outcome: 11 Non adherence to therapy
Study Oestrogen Oest + Prog (cont) Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Kurman 2000 84/296 167/880 73.0 1.75 [ 1.27, 2.41 ]
PEPI 1995 67/119 18/120 27.0 6.02 [ 3.55, 10.21 ]
Total (95% CI) 415 1000 100.0 2.44 [ 1.86, 3.21 ]
Total events: 151 (Oestrogen), 185 (Oest + Prog (cont))
Test for heterogeneity chi-square=15.32 df=1 p=<0.0001 I =93.5%
Test for overall effect z=6.37 p<0.00001
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Comparison 11. Endometrial hyperplasia at 6 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 05 OESTROGEN VS OESTROGEN + PROGESTAGEN (sequential)
Outcome: 01 Endometrial hyperplasia at 6 months
Study Oestrogen O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 CEE 0.625mg vs CEE0.625mg + MPA 5 mg (11 days)
Gelfand 1989 4/27 1/25 16.7 3.39 [ 0.54, 21.07 ]
Subtotal (95% CI) 27 25 16.7 3.39 [ 0.54, 21.07 ]
Total events: 4 (Oestrogen), 1 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=1.31 p=0.2
02 CEE 1.25mg vs CEE 1.25mg + MPA 5mg (11 days)
Gelfand 1989 4/23 0/20 13.4 7.49 [ 0.97, 57.53 ]
Subtotal (95% CI) 23 20 13.4 7.49 [ 0.97, 57.53 ]
Total events: 4 (Oestrogen), 0 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=1.94 p=0.05
03 CEE 0.625mg vs CEE 0.625mg + MPA 5mg or 10mg (14 days)
MSG 1994 21/298 1/585 69.8 16.90 [ 6.91, 41.33 ]
Subtotal (95% CI) 298 585 69.8 16.90 [ 6.91, 41.33 ]
Total events: 21 (Oestrogen), 1 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=6.20 p<0.00001
0.001 0.01 0.1 1 10 100 1000
Favours O Favours O + P (Continued . . . )
53Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Copyright © 2004 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
(. . . Continued)
Study Oestrogen O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Total (95% CI) 348 630 100.0 11.58 [ 5.48, 24.45 ]
Total events: 29 (Oestrogen), 2 (O + P)
Test for heterogeneity chi-square=2.60 df=2 p=0.27 I =23.0%
Test for overall effect z=6.42 p<0.00001
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Comparison 11. Endometrial hyperplasia at 12 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 05 OESTROGEN VS OESTROGEN + PROGESTAGEN (sequential)
Outcome: 02 Endometrial hyperplasia at 12 months
Study Oestrogen O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 CEE 0.625mg vs CEE 0.625mg + MPA 5 mg (11 days)
Gelfand 1989 8/27 0/25 4.5 9.32 [ 2.09, 41.49 ]
Subtotal (95% CI) 27 25 4.5 9.32 [ 2.09, 41.49 ]
Total events: 8 (Oestrogen), 0 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=2.93 p=0.003
02 CEE 1.25mg vs CEE 1.25mg + MPA 5mg (11 days)
Gelfand 1989 13/23 2/20 6.5 7.39 [ 2.13, 25.61 ]
Subtotal (95% CI) 23 20 6.5 7.39 [ 2.13, 25.61 ]
Total events: 13 (Oestrogen), 2 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=3.16 p=0.002
03 CEE 0.625mg vs CEE 0.625mg + MPA 5mg or 10mg (14 days)
MSG 1994 57/283 3/549 32.6 18.63 [ 10.70, 32.43 ]
Subtotal (95% CI) 283 549 32.6 18.63 [ 10.70, 32.43 ]
Total events: 57 (Oestrogen), 3 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=10.35 p<0.00001
04 CEE 0.625mg vs CEE 0.625mg + MPA 10mg or MP 200mg (days 1-12)
PEPI 1995 25/119 3/238 15.0 15.25 [ 6.73, 34.53 ]
Subtotal (95% CI) 119 238 15.0 15.25 [ 6.73, 34.53 ]
Total events: 25 (Oestrogen), 3 (O + P)
Test for heterogeneity: not applicable
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(. . . Continued)
Study Oestrogen O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Test for overall effect z=6.53 p<0.00001
05 E2 1 mg vs E2 1 mg NGM 30 ug (3 days on 3 days off)
Corson 1999 25/88 16/260 17.9 8.46 [ 4.00, 17.88 ]
Subtotal (95% CI) 88 260 17.9 8.46 [ 4.00, 17.88 ]
Total events: 25 (Oestrogen), 16 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=5.59 p<0.00001
06 E2 1 mg vs E2 1 mg NGM 90ug (3 days on 3 days off)
Corson 1999 25/88 0/242 11.8 57.12 [ 22.75, 143.41 ]
Subtotal (95% CI) 88 242 11.8 57.12 [ 22.75, 143.41 ]
Total events: 25 (Oestrogen), 0 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=8.61 p<0.00001
07 E2 1mg vs E2 1 mg NGM 180 ug (3 days on 3 days off)
Corson 1999 25/88 0/243 11.8 57.76 [ 22.99, 145.15 ]
Subtotal (95% CI) 88 243 11.8 57.76 [ 22.99, 145.15 ]
Total events: 25 (Oestrogen), 0 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=8.63 p<0.00001
Total (95% CI) 716 1577 100.0 18.70 [ 13.63, 25.66 ]
Total events: 178 (Oestrogen), 24 (O + P)
Test for heterogeneity chi-square=18.94 df=6 p=0.004 I =68.3%
Test for overall effect z=18.14 p<0.00001
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Comparison 11. Endometrial hyperplasia at 24 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 05 OESTROGEN VS OESTROGEN + PROGESTAGEN (sequential)
Outcome: 03 Endometrial hyperplasia at 24 months
Study Oestrogen O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 CEE 0.625mg vs CEE 0.625mg + MPA 10mg or MP 200mg (days 1-12)
PEPI 1995 54/119 7/238 100.0 19.83 [ 11.06, 35.55 ]
Total (95% CI) 119 238 100.0 19.83 [ 11.06, 35.55 ]
Total events: 54 (Oestrogen), 7 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=10.03 p<0.00001
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Comparison 11. Endometrial hyperplasia at 36 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 05 OESTROGEN VS OESTROGEN + PROGESTAGEN (sequential)
Outcome: 04 Endometrial hyperplasia at 36 months
Study Oestrogen O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 CEE 0.625mg vs CEE 0.625mg + MPA 10mg or MP 200mg (days 1-12)
PEPI 1995 74/119 12/238 100.0 22.56 [ 13.49, 37.71 ]
Total (95% CI) 119 238 100.0 22.56 [ 13.49, 37.71 ]
Total events: 74 (Oestrogen), 12 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=11.89 p<0.00001
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Comparison 11. Unscheduled biopsy or D & C
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 05 OESTROGEN VS OESTROGEN + PROGESTAGEN (sequential)
Outcome: 05 Additional investigations (unscheduled biopsy)
Study Oestrogen O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
PEPI 1995 100/119 32/238 100.0 20.50 [ 13.01, 32.32 ]
Total (95% CI) 119 238 100.0 20.50 [ 13.01, 32.32 ]
Total events: 100 (Oestrogen), 32 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=13.01 p<0.00001
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Comparison 11. Endometrial cancer
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 05 OESTROGEN VS OESTROGEN + PROGESTAGEN (sequential)
Outcome: 06 Endometrial cancer
Study Oestrogen O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
MSG 1994 1/283 1/549 100.0 2.04 [ 0.11, 38.10 ]
x PEPI 1995 0/119 0/238 0.0 Not estimable
Total (95% CI) 402 787 100.0 2.04 [ 0.11, 38.10 ]
Total events: 1 (Oestrogen), 1 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=0.48 p=0.6
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Comparison 11. Irregular bleeding patterns <6 months after Rx
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 05 OESTROGEN VS OESTROGEN + PROGESTAGEN (sequential)
Outcome: 07 Irregular bleeding patterns <6 months after Rx
Study Oestrogen O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Total (95% CI) 0 0 0.0 Not estimable
Total events: 0 (Oestrogen), 0 (O + P)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
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Comparison 11. Irregular bleeding patterns >6 months after Rx
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 05 OESTROGEN VS OESTROGEN + PROGESTAGEN (sequential)
Outcome: 08 Irregular bleeding patterns >6 months after Rx
Study Oestrogen O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Gelfand 1989 27/50 6/45 100.0 5.90 [ 2.54, 13.69 ]
Total (95% CI) 50 45 100.0 5.90 [ 2.54, 13.69 ]
Total events: 27 (Oestrogen), 6 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=4.13 p=0.00004
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Comparison 11. Number of cycles of irregular bleeding
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 05 OESTROGEN VS OESTROGEN + PROGESTAGEN (sequential)
Outcome: 09 Number of cycles of irregular bleeding
Study Oestrogen O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
MSG 1994 532/3639 618/7504 100.0 1.99 [ 1.75, 2.27 ]
Total (95% CI) 3639 7504 100.0 1.99 [ 1.75, 2.27 ]
Total events: 532 (Oestrogen), 618 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=10.39 p<0.00001
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Comparison 11. Number of cycles of irregular spotting
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 05 OESTROGEN VS OESTROGEN + PROGESTAGEN (sequential)
Outcome: 10 Number of cycles of irregular spotting
Study Oestrogen O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
MSG 1994 358/3639 740/7504 100.0 1.00 [ 0.87, 1.14 ]
Total (95% CI) 3639 7504 100.0 1.00 [ 0.87, 1.14 ]
Total events: 358 (Oestrogen), 740 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=0.04 p=1
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Comparison 11. Non adherence to therapy
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 05 OESTROGEN VS OESTROGEN + PROGESTAGEN (sequential)
Outcome: 11 Irregular bleeding/spotting at 12 months
Study E2 O + P Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
01 E2 1mg vs E21mg NGM 30 ug-180 ug
Sulak 1999 21/304 118/923 100.0 0.51 [ 0.31, 0.82 ]
Total (95% CI) 304 923 100.0 0.51 [ 0.31, 0.82 ]
Total events: 21 (E2), 118 (O + P)
Test for heterogeneity: not applicable
Test for overall effect z=2.76 p=0.006
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Comparison 11. Endometrial hyperplasia at 6 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 07 OESTROGEN + PROGESTOGEN (sequential) vs PLACEBO
Outcome: 01 Endometrial hyperplasia at 12 months
Study O + P Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 CEE 0.625mg (day 1-28) + MPA 10mg or micronised prog 200mg (day 1-12)
PEPI 1995 3/238 0/119 48.0 4.52 [ 0.41, 50.18 ]
Subtotal (95% CI) 238 119 48.0 4.52 [ 0.41, 50.18 ]
Total events: 3 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=1.23 p=0.2
02 EV 2mg (day 1-21) + MPA 10mg (day 12-21)
Heikkinen 1997 2/24 1/25 52.0 2.09 [ 0.21, 21.13 ]
Subtotal (95% CI) 24 25 52.0 2.09 [ 0.21, 21.13 ]
Total events: 2 (O + P), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.63 p=0.5
03 CEE 0.625 mg/d plus medroxyprogesterone acetate 5 mg/d for 13 days every 3 months
x Pinto 2003 0/13 0/12 0.0 Not estimable
Subtotal (95% CI) 13 12 0.0 Not estimable
Total events: 0 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 275 156 100.0 3.03 [ 0.57, 16.05 ]
Total events: 5 (O + P), 1 (Placebo)
Test for heterogeneity chi-square=0.20 df=1 p=0.65 I =0.0%
Test for overall effect z=1.30 p=0.2
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Comparison 11. Endometrial hyperplasia at 12 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 07 OESTROGEN + PROGESTOGEN (sequential) vs PLACEBO
Outcome: 02 Endometrial hyperplasia at 24 months
Study O + P Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 E2 2mg (day 1-22), E2 1mg (day 23-28) + NA 1mg (day 13-22)
x Obel 1993 0/45 0/45 0.0 Not estimable
Subtotal (95% CI) 45 45 0.0 Not estimable
Total events: 0 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 EV 2mg (1-21) + MPA 10mg (12-21)
Heikkinen 1997 3/23 1/25 37.9 3.19 [ 0.42, 24.21 ]
Subtotal (95% CI) 23 25 37.9 3.19 [ 0.42, 24.21 ]
Total events: 3 (O + P), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=1.12 p=0.3
03 CEE 0.625mg (day 1-28) + MPA 10mg or MP 200mg (day 1-12)
PEPI 1995 7/238 0/119 62.1 4.60 [ 0.94, 22.43 ]
Subtotal (95% CI) 238 119 62.1 4.60 [ 0.94, 22.43 ]
Total events: 7 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=1.89 p=0.06
04 17B E 1mg/5 mg dydro(days 14-28)
x Ferenczy 2002 0/100 0/16 0.0 Not estimable
Subtotal (95% CI) 100 16 0.0 Not estimable
Total events: 0 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
05 17B E 1 mg/10 mg dydro(days 14-28)
x Ferenczy 2002 0/95 0/16 0.0 Not estimable
Subtotal (95% CI) 95 16 0.0 Not estimable
Total events: 0 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
06 17B E 2 mg/10 mg dydro(days 14-28)
x Ferenczy 2002 0/88 0/16 0.0 Not estimable
Subtotal (95% CI) 88 16 0.0 Not estimable
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(. . . Continued)
Study O + P Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Total events: 0 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
07 17B E 2 mg/20 mg dydro(days 14-28)
x Ferenczy 2002 0/96 0/15 0.0 Not estimable
Subtotal (95% CI) 96 15 0.0 Not estimable
Total events: 0 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 685 252 100.0 4.00 [ 1.15, 13.95 ]
Total events: 10 (O + P), 1 (Placebo)
Test for heterogeneity chi-square=0.08 df=1 p=0.78 I =0.0%
Test for overall effect z=2.18 p=0.03
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Comparison 11. Endometrial hyperplasia at 24 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 07 OESTROGEN + PROGESTOGEN (sequential) vs PLACEBO
Outcome: 03 Endometrial hyperplasia at 36 months
Study O + P Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 CEE 0.625mg (day 1-28) + MPA 10mg or MP 200mg (day 1-12)
PEPI 1995 12/238 2/119 100.0 2.43 [ 0.78, 7.55 ]
Total (95% CI) 238 119 100.0 2.43 [ 0.78, 7.55 ]
Total events: 12 (O + P), 2 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=1.54 p=0.1
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Comparison 11. Endometrial hyperplasia at 36 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 07 OESTROGEN + PROGESTOGEN (sequential) vs PLACEBO
Outcome: 04 Additional investigations (unscheduled biopsy)
Study O + P Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
PEPI 1995 32/238 11/119 100.0 1.49 [ 0.76, 2.92 ]
Total (95% CI) 238 119 100.0 1.49 [ 0.76, 2.92 ]
Total events: 32 (O + P), 11 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=1.15 p=0.3
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Comparison 11. Unscheduled biopsy or D & C
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 07 OESTROGEN + PROGESTOGEN (sequential) vs PLACEBO
Outcome: 05 Endometrial cancer
Study O + P Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
01 0.625 mg/d CEE +10 mg/d MPA(day 1-12)
PEPI 1995 0/120 1/30 31.7 0.01 [ 0.00, 0.90 ]
Subtotal (95% CI) 120 30 31.7 0.01 [ 0.00, 0.90 ]
Total events: 0 (O + P), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=2.00 p=0.05
02 0.625 mg/d CEE + 200mg/cyclic micronized progesterone(days 1-12)
x PEPI 1995 0/120 0/30 0.0 Not estimable
Subtotal (95% CI) 120 30 0.0 Not estimable
Total events: 0 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
03 17B E 1 mg/5 mg dydrogesterone
Ferenczy 2002 1/100 0/15 22.5 3.16 [ 0.01, 1063.90 ]
Subtotal (95% CI) 100 15 22.5 3.16 [ 0.01, 1063.90 ]
Total events: 1 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.39 p=0.7
04 17B E 1 mg/10 mg dydrogesterone
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(. . . Continued)
Study O + P Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
x Ferenczy 2002 0/95 0/15 0.0 Not estimable
Subtotal (95% CI) 95 15 0.0 Not estimable
Total events: 0 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
05 17B E 2 mg/10 mg dydrogesterone
x Ferenczy 2002 0/88 0/15 0.0 Not estimable
Subtotal (95% CI) 88 15 0.0 Not estimable
Total events: 0 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
06 17 B E 2 mg/20 mg dydrogesterone
Ferenczy 2002 2/96 0/15 45.9 3.21 [ 0.05, 188.54 ]
Subtotal (95% CI) 96 15 45.9 3.21 [ 0.05, 188.54 ]
Total events: 2 (O + P), 0 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.56 p=0.6
Total (95% CI) 619 120 100.0 0.45 [ 0.03, 7.15 ]
Total events: 3 (O + P), 1 (Placebo)
Test for heterogeneity chi-square=4.15 df=2 p=0.13 I =51.8%
Test for overall effect z=0.56 p=0.6
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Comparison 11. Endometrial carcinoma
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 07 OESTROGEN + PROGESTOGEN (sequential) vs PLACEBO
Outcome: 06 Irregular bleeding patterns <6 months after treatment
Study O + P Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Obel 1993 2/48 3/48 100.0 0.66 [ 0.11, 3.95 ]
Total (95% CI) 48 48 100.0 0.66 [ 0.11, 3.95 ]
Total events: 2 (O + P), 3 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.46 p=0.6
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Comparison 11. Irregular bleeding patterns <6 months after treatment
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 07 OESTROGEN + PROGESTOGEN (sequential) vs PLACEBO
Outcome: 07 Irregular bleeding patterns >=6 months after treatment
Study O + P Placebo Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Hagen 1982 4/43 10/54 57.9 0.48 [ 0.15, 1.49 ]
Marslew 1991 6/38 0/19 23.6 5.19 [ 0.88, 30.74 ]
Marslew 1992 3/19 0/24 13.7 10.77 [ 1.04, 111.19 ]
Obel 1993 0/45 1/45 4.8 0.14 [ 0.00, 6.82 ]
Total (95% CI) 145 142 100.0 1.21 [ 0.51, 2.86 ]
Total events: 13 (O + P), 11 (Placebo)
Test for heterogeneity chi-square=9.72 df=3 p=0.02 I =69.1%
Test for overall effect z=0.43 p=0.7
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Comparison 11. Irregular bleeding patterns >=6 months after treatment
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 07 OESTROGEN + PROGESTOGEN (sequential) vs PLACEBO
Outcome: 08 Mean number of excess bleeding episodes(36 months)
Study O + P Placebo Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 CEE(0.625 mg)/MPA(10mg for 12 days of month)
Simon 2003 93 1.70 (0.80) 91 1.50 (1.00) 47.6 0.20 [ -0.06, 0.46 ]
Subtotal (95% CI) 93 91 47.6 0.20 [ -0.06, 0.46 ]
Test for heterogeneity: not applicable
Test for overall effect z=1.50 p=0.1
02 CEE(0.625 mg)/MP (200 mg for 12 days of month)
Simon 2003 94 1.50 (0.70) 91 1.50 (1.00) 52.4 0.00 [ -0.25, 0.25 ]
Subtotal (95% CI) 94 91 52.4 0.00 [ -0.25, 0.25 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.00 p=1
Total (95% CI) 187 182 100.0 0.10 [ -0.09, 0.28 ]
Test for heterogeneity chi-square=1.17 df=1 p=0.28 I =14.8%
Test for overall effect z=1.03 p=0.3
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Comparison 11. Non adherence to therapy
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 07 OESTROGEN + PROGESTOGEN (sequential) vs PLACEBO
Outcome: 09 Withdrawal due to adverse events
Study O + P Placebo Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
01 17B E 1-2mg/5-10mg dydrogesterone
Ferenczy 2002 71/379 12/63 100.0 0.98 [ 0.50, 1.93 ]
Total (95% CI) 379 63 100.0 0.98 [ 0.50, 1.93 ]
Total events: 71 (O + P), 12 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.06 p=1
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Comparison 11. Endometrial hyperplasia at 12 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 08 OESTROGEN + PROGESTOGEN (continuous) VS OESTROGEN + PROGESTOGEN (sequential)
Outcome: 01 Endometrial hyperplasia at 6 months
Study Continuous O + P Sequential O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
MSG 1994 1/586 1/585 100.0 1.00 [ 0.06, 15.98 ]
Total (95% CI) 586 585 100.0 1.00 [ 0.06, 15.98 ]
Total events: 1 (Continuous O + P), 1 (Sequential O + P)
Test for heterogeneity: not applicable
Test for overall effect z=0.00 p=1
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Comparison 11. Endometrial hyperplasia at 24 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 08 OESTROGEN + PROGESTOGEN (continuous) VS OESTROGEN + PROGESTOGEN (sequential)
Outcome: 02 Endometrial hyperplasia at 12 months
Study Continuous O + P Sequential O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
MSG 1994 2/553 3/549 65.2 0.66 [ 0.11, 3.85 ]
PEPI 1995 0/120 3/238 34.8 0.22 [ 0.02, 2.44 ]
x Ylikorkala 2002 0/157 0/125 0.0 Not estimable
Total (95% CI) 830 912 100.0 0.45 [ 0.11, 1.87 ]
Total events: 2 (Continuous O + P), 6 (Sequential O + P)
Test for heterogeneity chi-square=0.53 df=1 p=0.47 I =0.0%
Test for overall effect z=1.10 p=0.3
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Comparison 11. Endometrial hyperplasia at 36 months
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 08 OESTROGEN + PROGESTOGEN (continuous) VS OESTROGEN + PROGESTOGEN (sequential)
Outcome: 03 Endometrial hyperplasia at 24 months
Study Continuous O + P Sequential O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
x Obel 1993 0/39 0/45 0.0 Not estimable
PEPI 1995 1/120 7/238 100.0 0.38 [ 0.09, 1.68 ]
Total (95% CI) 159 283 100.0 0.38 [ 0.09, 1.68 ]
Total events: 1 (Continuous O + P), 7 (Sequential O + P)
Test for heterogeneity: not applicable
Test for overall effect z=1.27 p=0.2
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Comparison 11. Unscheduled biopsy or D & C
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 08 OESTROGEN + PROGESTOGEN (continuous) VS OESTROGEN + PROGESTOGEN (sequential)
Outcome: 04 Endometrial hyperplasia at 36 months
Study Continuous O + P Sequential O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
PEPI 1995 1/120 12/238 100.0 0.30 [ 0.09, 0.97 ]
Total (95% CI) 120 238 100.0 0.30 [ 0.09, 0.97 ]
Total events: 1 (Continuous O + P), 12 (Sequential O + P)
Test for heterogeneity: not applicable
Test for overall effect z=2.01 p=0.04
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Comparison 11. Endometrial cancer
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 08 OESTROGEN + PROGESTOGEN (continuous) VS OESTROGEN + PROGESTOGEN (sequential)
Outcome: 05 Endometrial cancer
Study Continuous O + P Sequential O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
MSG 1994 0/553 1/549 100.0 0.13 [ 0.00, 6.77 ]
x PEPI 1995 0/120 0/238 0.0 Not estimable
Total (95% CI) 673 787 100.0 0.13 [ 0.00, 6.77 ]
Total events: 0 (Continuous O + P), 1 (Sequential O + P)
Test for heterogeneity: not applicable
Test for overall effect z=1.00 p=0.3
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Comparison 11. Irregular bleeding patterns <6 months after treatment
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 08 OESTROGEN + PROGESTOGEN (continuous) VS OESTROGEN + PROGESTOGEN (sequential)
Outcome: 06 Irregular bleeding patterns <6 months after treatment
Study Continuous O + P Sequential O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Obel 1993 6/42 2/48 78.2 3.44 [ 0.81, 14.62 ]
Williams 1990 3/56 2/8 21.8 0.07 [ 0.00, 1.06 ]
Total (95% CI) 98 56 100.0 1.46 [ 0.41, 5.26 ]
Total events: 9 (Continuous O + P), 4 (Sequential O + P)
Test for heterogeneity chi-square=6.15 df=1 p=0.01 I =83.7%
Test for overall effect z=0.58 p=0.6
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Comparison 11. Irregular bleeding patterns >=6 months after treatment
Review: Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding
Comparison: 08 OESTROGEN + PROGESTOGEN (continuous) VS OESTROGEN + PROGESTOGEN (sequential)
Outcome: 07 Irregular bleeding patterns >=6 months after treatment
Study Continuous O + P Sequential O + P Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N 95% CI (%) 95% CI
Luciano 1993 0/21 1/8 7.0 0.03 [ 0.00, 2.14 ]
Marslew 1992 0/19 3/19 24.7 0.12 [ 0.01, 1.24 ]
Obel 1993 5/39 0/45 41.2 9.61 [ 1.59, 58.23 ]
Williams 1990 4/56 4/8 27.1 0.02 [ 0.00, 0.20 ]
Total (95% CI) 135 80 100.0 0.41 [ 0.13, 1.31 ]
Total events: 9 (Continuous O + P), 8 (Sequential O + P)
Test for heterogeneity chi-square=21.17 df=3 p=<0.0001 I =85.8%
Test for overall effect z=1.50 p=0.1
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